Stockwinners Market Radar for June 03, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:31 EDT Rio Tinto to invest $143M to develop R&D facility in Western Australia - The company states: "Rio Tinto will invest $143 million to develop a research and development facility in Western Australia to further assess the effectiveness of its low-carbon ironmaking process, BioIronTM, to support decarbonising the global steel value chain. The development of the BioIron Research and Development Facility in the Rockingham Strategic Industrial Area, south of Perth, follows successful trials of the innovative ironmaking process in a small-scale pilot plant in Germany. BioIron uses raw biomass and microwave energy instead of coal to convert Pilbara iron ore to metallic iron in the steelmaking process. When combined with the use of renewable energy and carbon-circulation by fast-growing biomass, BioIron has the potential to reduce carbon emissions by up to 95% compared with the current blast furnace method. The BioIron facility will include a pilot plant that will be ten times bigger than its predecessor in Germany. It will also be the first time the innovative steelmaking process has been tested at a semi-industrial scale, capable of producing one tonne of direct reduced iron per hour. It will provide the required data to assess further scaling of the technology to a larger demonstration plant."

20:02 EDT Cathie Wood's ARK Investment buys 168K shares of PagerDuty today

19:50 EDT LadRx, ImmunityBio mutually agree to terminate Aldoxorubicin license - The company states: "LadRx is pleased to announce that the Company and NantCell, Inc., together with NantCell's parent company ImmunityBio, Inc., have agreed to a mutual termination of the license of aldoxorubicin entered into in 2017. With the termination of the license agreement between LadRx and NantCell, LadRx regains control of aldoxorubicin. In 2023, LadRx transferred the royalty and milestone rights of arimoclomol and aldoxorubicin to XOMA Corporation (XOMA) in exchange for $5 million in upfront gross proceeds, up to an additional $2 million for milestones related to arimoclomol and $5 million for milestones related to aldoxorubicin. XOMA consented to the mutual termination of the LadRx-NantCell agreement in order to facilitate the return of the program to LadRx. In parallel, LadRx and XOMA have amended their 2023 Royalty Purchase Agreement to provide XOMA with a low-single-digit synthetic royalty on aldoxorubicin and a mid-single-digit percentage of any economics derived by LadRx from future out-license agreements related to aldoxorubicin. The agreement between LadRx and XOMA regarding future royalties and milestones associated with arimoclomol is not affected by the termination of the aldoxorubicin license between LadRx and NantCell."

19:21 EDT Carnival to absorb P&O Cruises Australia into Carnival Cruise Line - The company states: "Carnival announced that in March 2025, the company will sunset the P&O Cruises Australia brand and fold the Australia operations into Carnival Cruise Line, the most popular cruise line in the world. This change is the latest in a series of strategic moves designed to increase guest capacity for Carnival Cruise Line, the company's flagship brand and the highest-returning brand in Carnival Corporation's global portfolio. This will result in the addition of eight new ships to Carnival Cruise Line's fleet since 2021, including the successful shift of three vessels from sister brand Costa Cruises. In addition, the company recently placed its first new ship order in half a decade for two new Excel-class cruise ships to join Carnival Cruise Line in 2027 and 2028. In addition to further optimizing the composition of Carnival Corporation's global brand portfolio, the realignment will strengthen the company's performance in the South Pacific through numerous operational efficiencies."

18:27 EDT Annexon up 48% afterhours at $6.79 - Shares of Annexon are up 48% or $2.21 afterhours at $6.79. After the market close, the company announced that it will "host a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m. ET to discuss GBS phase 3 data."

18:01 EDT First Guaranty Bancshares names Michael Mineer as CEO - First Guaranty Bancshares announced Michael Mineer has been appointed as First Guaranty Bancshares and First Guaranty Bank's President and CEO. He will succeed Alton Lewis, who announced his retirement at the end of May. Mineer has been a part of the First Guaranty family as the Mideast Area President since 2021 and brings over 35 years of banking experience to his new role. Most recently, Mineer served as President and CEO of Citizens Deposit Bank in Vanceburg, KY, since 2003.

17:32 EDT CN Energy receives noncompliance notification from Nasdaq - CN Energy announced that it received a written notice from Nasdaq. The notice notifies that the company is not in full compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the company's Class A ordinary shares for the 30 consecutive business days from April 15 through May 24, the company no longer meets the minimum bid price requirement.

17:24 EDT Radiant Logistics acquires operations of Cascade Transportation, no terms - Radiant Logistics announced it has acquired the operations Cascade Transportation, a Seattle-based, privately held company that provides a full range of customized time critical domestic and international transportation and logistics services. The company structured the transaction similar to its previous transactions, with a portion of the expected purchase price payable in subsequent periods based on the future performance of the acquired operations. Founded in 1982, Cascade services a diversified account base including retail, e-commerce, production furniture and tradeshow industries. From inception through the date of acquisition, Cascade operated as part of a competing transportation group. On a post-closing basis, Cascade will continue under the current leadership and operate as Radiant Global Logistics.

17:17 EDT Northrop Grumman awarded $119.58M Navy contract - Northrop Grumman was awarded a $119.58M long-term, requirements contract for the repair of 17 weapon replaceable assemblies and shop replaceable assemblies in support of the E-2 aircrafts. This is a nineteen-month contract with no option periods, and work will be completed by December 2025. No funds will be obligated at time of award and funds will not expire at the end of the current fiscal year. Appropriate fiscal year working capital funds will be used as delivery orders are issued. One company was solicited for this sole-source requirement pursuant to the authority set forth in 10 U.S. Code 2304 (c)(1), with one offer received. Naval Supply Systems Command Weapon Systems Support is the contracting activity.

17:11 EDT Marin Software announces expanded Amazon integration - Marin Software (MRIN) announces major enhancements to its Amazon (AMZN) integration. This update includes Sponsored TV, non-endemic advertising, and access to the Demand-Side Platform globally, making it easier for brands not selling on Amazon to engage with the Amazon audience. "Our enhanced Amazon offering represents a major leap forward in our commitment to helping digital marketers connect with consumers in the most impactful ways. By incorporating Sponsored TV, expanding DSP capabilities globally, and introducing non-endemic advertising options, we are enabling brands to maximize their reach and effectiveness within the Amazon family of brands," said Chris Lein, CEO of Marin Software.

17:01 EDT Asure announces new agreement with Vensure Employer Solutions - Asure Software is "pleased to announce a new agreement with Vensure Employer Solutions, a premier provider of HR technology and global business process outsourcing. This collaboration will introduce the PrismHR TAX platform, delivering comprehensive payroll tax management services for PrismHR clients and Vensure's internal operations. The new PrismHR TAX platform leverages Asure's advanced payroll tax technology to reduce financial risk for companies while ensuring compliance with the latest federal, state, and local tax regulations. This platform enhances Vensure's already robust PrismHR technology portfolio, which includes Professional Employer Organization, Administrative Service Organization, and Human Capital Management solutions."

16:59 EDT Essential Properties Realty Trust raises quarterly dividend to 29c per share - Essential Properties Realty Trust announced that its Board of Directors declared a quarterly cash dividend of 29c per share of common stock for the second quarter of 2024. On an annualized basis the second quarter 2024 dividend of 29c equals $1.16 per share, an increase of 2c per share compared to the previous annualized dividend. The dividend is payable on July 12 to stockholders of record as of the close of business on June 28.

16:41 EDT VP of Cytokinetics Robert Wong sells $636K in company shares - VP of Cytokinetics Robert Wong disclosed the sale of 13,011 shares of company stock at $48.88 per share on June 3 for a total transaction aount of $635,978.

16:33 EDT Zapata AI announces Derron Blakely as general counsel - Zapata AI (ZPTA) announced that Derron Blakely has joined the company as its general counsel, effective immediately. Blakely brings a legal background at public companies in the AI and defense industries. In his most recent position as general counsel at C3.ai (AI), Blakely played a role in commercial and federal contracting, compliance, employment, litigation, and corporate governance.

16:31 EDT Oshkosh CFO Pack named president of Vocational segment - Oshkosh Corporation announced that Michael Pack, executive vice president and chief financial officer of Oshkosh, has been appointed as president of the Vocational segment, effective immediately, succeeding Jim Johnson in that role. Mr. Johnson is retiring from the Company, effective June 30, 2024. Oshkosh has initiated a search process with the assistance of a leading executive search firm to identify the Company's next chief financial officer. Pack will continue to serve as CFO until a successor is named. "Mike has spent much of his 18-year tenure at Oshkosh in leadership roles in our Fire & Emergency and Commercial segments, which were combined in 2023 to form our Vocational segment. We are excited that he is returning to lead this great business," said John Pfeifer, president and chief executive officer of Oshkosh Corporation. "Mike is a proven leader who knows the business well and brings established relationships with our customers, dealers and team members to his new role. We have talented teams in both our finance and Vocational organizations to ensure a smooth transition."

16:31 EDT Safe Bulkers to acquire one Japanese Kamsarmax class dry-bulk vessel, no terms - Safe Bulkers announced that it has entered into an agreement for the acquisition of a Japanese, 82,000 dwt, dry-bulk, Kamsarmax class vessel, with a scheduled delivery date within the first quarter of 2027. The newbuild vessel is designed to meet the Phase 3 requirements of Energy Efficiency Design Index related to the reduction of greenhouse gas emissions as adopted by the International Maritime Organization, and also comply with the latest NOx emissions regulation, NOx-Tier I. This newbuild vessel is a sister vessel to a number of newbuilds in our orderbook with advanced energy efficiency characteristics resulting to lower fuel consumption. The company has already taken delivery of nine IMO GHG Phase 3 - NOx Tier III vessels. Including this agreement, the Company has an outstanding orderbook of nine newbuild vessels, two of which are methanol dual fuel, with scheduled deliveries one in 2024, two in 2025, four in 2026, and two in 2027. Dr. Loukas Barmparis, President of the company, commented: "We are entering in this newbuild order consistent with our fleet renewal strategy, aiming to create a resilient company with a young and efficient fleet within the ever developing stringent CO2 emission regulations environment."

16:25 EDT Myriad Genetics announces RiskScore study results published - Myriad Genetics announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics, or ACMG, published a new study validating RiskScore, Myriad's breast cancer risk assessment tool integrated into its MyRisk Hereditary Cancer Test. RiskScore combines a polygenic risk score, or PRS, validated for all ancestries with the Tyrer-Cuzick model, a widely used breast cancer risk assessment calculator. The study - first shared as a Spotlight Presentation at the 2022 San Antonio Breast Cancer Symposium - examined real-world patient outcomes from more than 130,000 women who have taken Myriad's MyRisk Hereditary Cancer Test with RiskScore. The study demonstrated that RiskScore was more accurate at stratifying women at high- or low-risk of developing breast cancer than the Tyrer-Cuzick risk calculator alone. In fact, the integration of RiskScore with Tyrer-Cuzick improved predictive accuracy by roughly two-fold over Tyrer-Cuzick alone.

16:22 EDT Contineum names John Healy as General Counsel - Contineum Therapeutics announced the appointment of John Healy as General Counsel & Corporate Secretary. Mr. Healy is a business and transactional attorney with over two decades of experience in the biotechnology industry, including as a corporate associate within top tier law firms, as a public company general counsel and as a trusted legal advisor providing a broad range of legal consulting support to the executive management teams of his private and public consulting clients.

16:20 EDT F9 Investments responds to latest shareholder communication by LL Flooring - F9 Investments, which together with its affiliates collectively owns approximately 8.85% of LL Flooring Holdings common stock and is the Company's largest shareholder, issued the following statement in response to LL Flooring's claims regarding F9's intentions and the strategic capability of the Company's current Board of Directors. Tom Sullivan, Founder of F9 and founder and former CEO and Chairman of Lumber Liquidators, LL Flooring's predecessor company, said, "As the largest shareholder of LL Flooring, we are seeking three seats on the Company's nine-person Board to protect the value of our investment and that of all stakeholders. As such, we are clearly not seeking control of the Company. Rather, as we have stated previously, we believe LL Flooring desperately needs strong leaders in the boardroom who can provide much-needed oversight and who bring a track record of creating value. Notably, under the incumbent Board, LL's stock price has plummeted more than 63%, 93%, and 83% on a 1-, 3-, and 5-year basis, respectively, and the Board's so-called five step strategic plan has been an abject failure. Moreover, we believe the Board's sale process has been a complete sham, as the Board has disclosed that it has received multiple premium offers from bona fide bidders only to reject or ignore them as the Company's share price craters. We also believe the Board's stated plan to enter into a sale-leaseback commitment for its distribution center is shortsighted and will most likely increase expenses and be value destructive in the long run. We believe that the claims in the letter LL Flooring mailed to shareholders today are misleading and delusional and lead us to believe that the Board is only seeking to entrench itself and fails to recognize the dire state of the Company despite the fact that it recently disclosed that its auditors believe that LL Flooring may be at risk of going out of business if its financial condition continues to deteriorate."

16:17 EDT FibroGen, Regeneron in deal for oncology assets in evaluation combo study - FibroGen (FGEN) announced a clinical trial supply agreement with Regeneron Pharmaceuticals (REGN) to evaluate FibroGen's immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron's anti-PD-1 therapy, LIBTAYO or cemiplimab, in patients with solid tumors. "We are very excited to collaborate with Regeneron Pharmaceuticals to evaluate two separate novel combination approaches to treat patients with select solid tumors," said Deyaa Adib, M.D., Chief Medical Officer of FibroGen. "We believe that the mechanisms of action for both FG-3165 and FG-3175 have the potential to be synergistic with cemiplimab, providing the possibility for an improvement in clinical outcomes for patients. We look forward to building a collaborative relationship with Regeneron, who is a leader in oncology therapeutic products development and commercialization." FG-3165 targets Gal9, which binds multiple immune checkpoints on lymphocytes that suppress T and natural killer NK cell activation. FG-3175 targets CCR8, a receptor frequently over-expressed on T regulatory cells in solid tumors. Both FG-3165 and FG-3175 have demonstrated complementary mechanisms of action with PD-1 inhibitors preclinically, and the Company believes that combining LIBTAYO( with either FG-3165 or FG-3175 may result in added clinical benefit for patients.

16:15 EDT Inogen publishes study linking portable oxygen concentrators, higher survival - Inogen "shared the results of a study published in the journal Pulmonary Therapy, demonstrating the association of portable oxygen concentrators with increased survival and cost-effectiveness ratio when compared to other long-term oxygen therapies. The study sourced data from the French national healthcare system database, the Systeme National des Donnees de Sante. With a sample size of over 244,000 adult long-term oxygen therapy patients from 2013-2020, it is likely the largest retrospective claims database assessment study of long-term oxygen therapy to date. The results showed that portable oxygen concentrator (POC) use, either alone or in combination with other oxygen modalities, was associated with improved survival and similar healthcare resource use, such as hospitalizations and specialist visits, compared to stationary concentrators, compressed tanks and liquid oxygen. Additionally, based on the incremental cost-effectiveness ratio, POCs were cost-effective compared to stationary concentrators, compressed tanks, and liquid oxygen."

16:13 EDT G.J. Heart joins Dutch Bros' board of directors - Dutch Bros (BROS) has "announced the appointment of G.J. Hart to its Board of Directors, where he will serve as an independent director and as Chair of the Compensation Committee. Hart brings four decades of executive experience at foodservice operations including Red Robin Gourmet Burgers, California Pizza Kitchen, Torchy's Tacos and Texas Roadhouse, and has a proven track record of growing casual and fast-casual dining concepts. Hart has spent nearly 40 years scaling both private and public companies. Since September 2022, Hart has served as President and Chief Executive Officer of Red Robin Gourmet Burgers (RRGB)".

16:11 EDT Nova Scotia provids coverage for DexCom glucose monitoring - Dexcom "announced that residents of Nova Scotia living with either type 1 or type 2 diabetes who use intensive insulin and meet eligibility criteria now have coverage for Dexcom G6 and Dexcom G7 continuous glucose monitoring systems. This news is the latest in a series of provincial announcements regarding coverage eligibility for Dexcom G6 and G7 CGM systems. New Brunswick, Newfoundland and Labrador, British Columbia, Manitoba, and Prince Edward Island have recently adapted their respective provincial coverage programs to include or expand coverage for continuous glucose monitors, specifically Dexcom G6 and G7."

16:08 EDT CSG Systems acquires iCG Pay for $17M - CSG "announced it has acquired iCheckGateway.com, a North American ACH and credit card payment processing company. Management expects this acquisition to be accretive to CSG's 2024 profitability. iCG Pay has a rapidly growing merchant customer base in high recurring revenue industry verticals including financial services, insurance, utilities and government. Both CSG and iCG Pay provide market leading solutions in ACH and credit card processing such that merchants and independent software vendor partners will benefit greatly from our combined offerings once the two platforms are fully integrated. The acquisition also adds attractive new ISV channel partnerships and a proven team of payments leaders who will help extend CSG's leadership in the North American payments markets."

16:07 EDT Scholar Rock presents new deata from SRK-181 Phase 1 trial at ASCO - Scholar Rock "announced encouraging data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhibitor of latent TGFbeta1 activation, in combination with pembrolizumab in patients with advanced solid tumors. The results show encouraging responses in heavily pretreated and anti-PD-(L)1 resistant patients across multiple tumor types. Data were shared in an oral presentation during the American Society of Clinical Oncology Annual Meeting on June 3 in Chicago. Safety data from all cohorts in the dose expansion phase (Part B; n=78 patients; 1500 mg q3w) continued to show SRK-181 was generally well tolerated when used in combination with pembrolizumab. One Grade 4 treatment-related adverse event of generalized dermatitis exfoliative was observed in one patient. No Grade 5 treatment-related AEs occurred. The only treatment-related serious adverse event related to SRK-181 or pembrolizumab that occurred in at least 2% of patients was pemphigoid. The most common AEs were rash, pruritis, fatigue, and diarrhea. Encouraging responses were observed in multiple tumor types, continuing to support proof-of-concept for SRK-181. The response was assessed by principal investigators based on RECIST 1.1 for patients across five cohorts: clear cell renal cell carcinoma, head and neck squamous cell carcinoma, melanoma, urothelial carcinoma, and non-small cell lung cancer. A summary of anti-tumor activity is presented in the table below; results for NSCLC (n=11) are not included because no response was observed. "

16:06 EDT Camping World president Moody, CFO Bell to retire - Camping World Holdings announced that the company's President, Brent Moody, plans to retire on December 31, 2024, with his resignation as President effective July 1, 2024. The company also announced its Chief Financial Officer, Karin Bell, plans to retire upon the filing of the company's Form 10-K for the year ended December 31, 2024, with her resignation as Chief Financial Officer effective July 1, 2024. In connection with Moody's resignation, Matthew Wagner will be appointed President, and will continue to serve as the company's principal operating officer. In connection with Bell's resignation, Tom Kirn will be appointed Chief Financial Officer, and will continue to serve as the company's principal accounting officer. Marcus Lemonis, Chairman and CEO of Camping World remarked, "Brent, Karin and I have been together since the beginning, helping both formulate and lead our company. With over 40 years of combined service, their commitment to the company is undeniable as Camping World would not be what it is today without them. Brent and Karin will continue to mentor the next generation of leaders in our company for years to come, with Brent continuing his role on our Board of Directors, while Karin will continue to serve in an advisory role for both myself and the senior management team." "I am very grateful to have spent over 20 years helping to grow the business," said Mr. Moody. "I am confident in Matt's demonstrated ability to lead and innovate across our company, I look forward to a smooth transition and am excited for the organization's future growth."

16:02 EDT Legend Biotech reports results from Phase 2 CARTITUDE-2 Cohort D Study - Legend Biotech Corporation announced results for the first time from the Phase 2 CARTITUDE-2 Cohort D study in multiple myeloma patients. Results showed patients with less than a complete response after front-line autologous stem cell transplant experienced deep and durable responses following a single infusion of CARVYKTI with or without lenalidomide maintenance. These data were presented as an oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting and will also be shared as an encore oral presentation at the 2024 European Hematology Association Congress. CARVYKTI is the first and only B-cell maturation antigen-targeted therapy approved for the treatment of patients with relapsed/refractory multiple myeloma as early as after first relapse. "Patients who achieve a less than complete response following ASCT may experience less durable response with future treatments," said Melissa Alsina, M.D., Head Myeloma BMT-CI Program, H. Lee Moffitt Cancer Center, and Research Institute. The outcomes from this study showed encouraging efficacy results and indicated the potential benefit of CARVYTKI in this patient population." At a median follow-up of 22 months, patients treated with CARVYKTI demonstrated a 94% overall response rate with all 16 patients achieving a CR or better. Of the 15 minimal residual disease-evaluable patients, 80% achieved MRD negativity at the 10-5 threshold. The median duration of response was not reached and the median time to first response was one month. Eighteen-month progression-free survival and overall survival rates were 94% each. Safety signals were consistent with the known safety profile of CARVYKTI. All patients had grade 3 or 4 treatment emergent adverse events including neutropenia, lymphopenia, thrombocytopenia, leukopenia, infections, or CRS. One patient had a secondary malignancy of grade 3 myelodysplastic syndromes. No cases of movement and neurocognitive treatment-emergent adverse events/parkinsonism were observed.

15:58 EDT Johnson & Johnson reports results from subgroup analysis of CARTITUDE-4 study - Johnson & Johnson announced results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. The data show CARVYKTI significantly improved progression-free survival, or PFS, compared to standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone for patients with lenalidomide-refractory multiple myeloma after one prior line of therapy, including patients with functional high-risk multiple myeloma. FHR was defined as progressive disease within 18 months after receiving autologous stem cell transplant or the start of initial frontline therapy in patients with no ASCT. These data were featured as an oral presentation at the 2024 American Society of Clinical Oncology, or ASCO, Annual Meeting and will also be shared at the 2024 European Hematology Association, or EHA, Congress, the company noted.

15:00 EDT Astellas Pharma's treatment of pancreatic cancer granted FDA orphan designation - According to a post on the FDA's website, Astellas Pharma's treatment of pancreatic cancer was granted orphan designation. Reference Link

13:58 EDT S&P Dow Jones says 'taking appropriate steps to mitigate' future interruptions - S&P Dow Jones Indices issued the following statement: "On 30 May 2024, S&P Global Inc. experienced an outage of certain applications and services commencing at approximately 10:41 am ET, which impacted S&P Dow Jones Indices' dissemination of its real-time indices. Service to S&P Dow Jones Indices' real-time indices was restored by 11:51 am ET, and service to the majority of S&P Global's applications and services was restored by close of business. S&P Dow Jones Indices takes these matters seriously and is taking appropriate steps to mitigate the risk of similar matters occurring in the future." Reference Link

13:27 EDT Inotiv announces agreement with DOJ to resolve Cumberland facility investigation - Inotiv announced that it reached an agreement with the U.S. Department of Justice to resolve a previously-announced criminal investigation into the shuttered canine breeding facility located in Cumberland, Virginia, which was operated originally by Envigo RMS LLC, a company acquired by Inotiv in November 2021. Before the United States District Court for the Western District of Virginia, Envigo RMS pleaded guilty to one misdemeanor count of conspiracy to violate the Animal Welfare Act and Envigo Global Services, Inc. pleaded guilty to one felony count of conspiracy to violate the Clean Water Act. Under the terms of the resolution, Inotiv agreed to make payments totaling $22M in fines, to be paid over a four-year period between 2025 and 2028. The first payment is due June of 2025. Additionally, Inotiv agreed to continue to make improvements to facilities and personnel related to the welfare of animals and will invest a minimum of $7M in these improvements over a period of three years, which is considered by the company to be in the ordinary course of business. As part of this resolution, Inotiv also has paid $3M, split between the Virginia Animal Fighting Taskforce and the Humane Society of the United States in acknowledgement of assistance provided to the U.S. Government's investigation, and $3.5M to the National Fish and Wildlife Foundation to fund environmental projects, studies, and initiatives adjacent to the Cumberland facility. Inotiv has also agreed to certain other non-monetary conditions as part of the resolution. In connection with the resolution, Inotiv has entered into an amendment to its credit facilities with its senior secured lenders to facilitate its compliance with the terms of the resolution. Inotiv issued the following statement: "Today's agreement will allow us to comprehensively resolve this matter, bringing to an end uncertainty around the investigation, and enabling the Company to focus our full attention on providing our customers with the tools and solutions they need to conduct critical drug discovery and development efforts that are essential to saving human lives. Inotiv's top priority has always been - and remains - practicing appropriate standards of animal welfare for our animals, while supporting the scientific objectives of the studies conducted. We strive to maintain facilities that are compliant with applicable federal, state, and local laws and regulations and consistent with our core value to always do the right thing. That is why we worked to reach this agreement, and why we have agreed to go above and beyond those legal requirements."

13:20 EDT Brookfield says in early stages for possible Tritax EuroBox offer - Brookfield Asset Management (BAM), through its private real estate investment funds, notes the recent press speculation in relation to Tritax EuroBox (TTAXF). Brookfield confirms it is in the early stages of a possible cash offer for the entire issued, and to be issued, share capital of Tritax EuroBox. Brookfield is now required, by no later than July 1, to either announce a firm intention to make an offer for the company or announce that it does not intend to make an offer.

13:14 EDT NYSE evaluating which LULD halts were erroneous for potential busts - In a system status update posted at 1:02 PM, the NYSE stated: "The following is the CTA SIP-provided list of symbols, which had LULD halts between 9:30 AM and 10:27 AM during this morning's issue. We are currently evaluating which LULD halts were erroneous (i.e., caused by erroneous bands published by the CTA SIP) versus correct halts resulting from correct price bands. Halts determined to have been caused by erroneous bands will be considered for potential busts." Reference Link

12:47 EDT OS Therapies reports 1-year EFS of 32.5% from ongoing Phase 2b trial - OS Therapies announced a clinical update for AOST-2121, its ongoing Phase 2b clinical trial of its immunotherapy OST-HER2 in patients with resected, recurrent osteosarcoma. The AOST-2121 study is designed to demonstrate efficacy in patients who have already had recurrent disease and are highly likely to recur again. A total of 18 OST-HER2 doses are administered once every three weeks, for a total 51 weeks. Radiographic evaluation of recurrence is evaluated throughout treatment. AOST-2121 has achieved full enrollment of 41 patients treated with OST-HER2 at 21 clinical trial sites across the United States. A few patients remain in the active treatment stage with the remainder in follow-up for overall survival. The primary endpoints for the AOST-2121 study are Event Free Survival at 12 months and Overall Survival at 36 months, with interim Overall Survival endpoints at 12 months and 24 months. Topline EFS data, interim 1-year OS data, as well as additional secondary data analyses are expected to be reported in the fourth quarter of 2024. No novel therapeutic interventions have improved the clinical outcomes for patients with resected, recurrent osteosarcoma in over 40 years. The clinical updates reported today include: 1-year EFS rate of 32.5% vs. 20% EFS rate for unsuccessful investigational therapeutic comparator; 1-year overall survival rate of 90.4%; 18-month overall survival rate of 90.4%; Treatment has been well tolerated and there have been no grade 3, 4 or 5 treatment-related adverse events reported for the 41 patients.

12:32 EDT Denali Capital Acquisition Corp trading resumes

12:27 EDT Denali Capital Acquisition Corp trading halted, volatility trading pause

12:20 EDT Embraer announces order for 20 E2 aircraft from Mexicana de Aviacion - Mexicana de Aviacion, Mexico's state-owned carrier, has ordered 20 Embraer E2 aircraft. The deal is for 10 E190-E2 and 10 E195-E2 jets. Deliveries will begin in 2Q25. Mexicana will configure the E190-E2 with 108 seats, and the E195-E2 with 132 seats - both in a single class layout. "Mexicana will be the first E2 operator in Mexico, benefitting from the E2's low operating costs and fuel efficiency, highlighting Mexicana and Embraer's commitment to sustainability, and improving the efficiency of aviation. With this strategic decision the Mexican state airline will grow and modernize its fleet, strengthening domestic and international connectivity to offer affordable and comfortable air travel, with the highest standards of safety and service," the company announced.

12:08 EDT Crinetics announces initial findings for atumelnant in two ongoing studies - Crinetics Pharmaceuticals announced initial findings from the development program of its second clinical product candidate, atumelnant, a novel, once-daily oral adrenocorticotropic hormone receptor antagonist. The results, presented at the Endocrine Society's annual meeting, include initial data from the Phase 1b/2a, open-label study in participants with ACTH-dependent Cushing's syndrome conducted in collaboration with the National Institutes of Health, and the Phase 2 open-label TouCAHn study in participants with congenital adrenal hyperplasia."Despite knowing about ACTH's pivotal role in the endocrine stress response for nearly a century, no other ACTH antagonist drug candidates have been developed and studied in humans. Achieving physiologically normal hormone levels is critical for people living with CAH and ADCS, and today's data show an impressive ability of atumelnant to reduce key disease drivers like A4 or cortisol to healthy levels," said Scott Struthers, Ph.D., founder and CEO of Crinetics. "These data also reinforce the strength of our in-house discovery engine and our ability to purposefully design medicines with groundbreaking mechanisms of action like atumelnant, the second novel drug candidate in our pipeline to have demonstrated remarkable results in clinical studies." Initial results from Cohort 1: Atumelnant resulted in profound, rapid and sustained reductions in key adrenal steroids that are hallmarks of CAH. 100% of participants had A4 levels below the upper limit of normal at two weeks with atumelnant, which was sustained through 12 weeks. Two-week data from the first four patients in Cohort 2 (40 mg atumelnant once daily) are also presented at ENDO2024. No severe or serious treatment emergent adverse events have been observed to date, and no participants have discontinued from the trial. All AEs to-date have been mild to moderate and transient. There were no significant changes in safety labs or electrocardiograms. The most common treatment-emergent adverse events included: fatigue, headache and upper respiratory tract infection.

12:04 EDT Coherent rises 17.8% - Coherent is up 17.8%, or $10.15 to $67.21.

12:02 EDT GameStop rises 27.9% - GameStop is up 27.9%, or $6.45 to $29.59.

12:01 EDT Oklo falls -9.7% - Oklo is down -9.7%, or -98c to $9.09.

11:57 EDT ChromaDex treatment of ataxia telangiectasia granted orphan designation - ChromaDex's treatment of ataxia telangiectasia was granted FDA orphan designation, according to a post to the agency's website. Reference Link

11:45 EDT NYSE Equities says technical issue resolved, all impacted stocks reopened - In a notice posted at 9:52 AM, NYSE (ICE) stated: "NYSE Equities is currently investigating a reported technical issue." In an update posted at 10:11 AM, NYSE added: "NYSE Equities continues to investigate a reported technical issue regarding LULD Bands," referring to the limit up and limit down bands. In another update posted at 11:08 AM, NYSE stated: "A technical issue with industry-wide price bands published by the CTA SIP triggered halts in a number of stocks listed on the NYSE Group exchanges this morning. Impacted stocks have since reopened (or are in the process of reopening) and the price bands issue has been resolved." In the latest update at 11:40 AM, NYSE stated: "All impacted stocks have reopened. All systems are currently operational." Reference Link

11:32 EDT Blackbaud appoints CAO Chad Anderson, CPO Sudop Datta to executive team - Blackbaud announced that Chief Accounting Officer Chad Anderson and Chief Product Officer Sudip Datta have been appointed to the company's executive leadership team. Anderson has been with Blackbaud since March 2013, successfully leading many key initiatives to mature, modernize and improve the efficiency and accuracy of the company's financial systems, processes and organization. Datta joined Blackbaud in 2022 to oversee the company's global product portfolio-including product lifecycles, roadmaps and strategy-contributing to growth, innovation and enhanced customer value.

11:06 EDT MidWestOne appoints Paul Ho-Sing-Loy as CIO, Elda Macias as CMO - MidWestOne Financial Group announced the hiring of three new executive leaders: Paul Ho-Sing-Loy, Executive Vice President and Chief Information Officer; Steve Heimermann, Executive Vice President and Head of Wealth Management; and Elda Macias, Senior Vice President and Chief Marketing Officer. Paul Ho-Sing-Loy joins MidWestOne from Lakeland Bank, where he served as Executive Vice President and Chief Information Officer. Steve Heimermann joins MidWestOne from Northern Trust Corporation where he was a Senior Vice President and Regional Senior Investment Officer. Elda Macias joins MidWestOne from Securian Financial where she developed and led a customer experience strategy and practice, with a focus on digital transformation, in addition to responsibility for the U.S and Canadian websites, customer insights, and user experience.

11:01 EDT Humana, UAB Health System sign agreement - The University of Alabama at Birmingham Health System and Humana have signed an in-network agreement, expanding access to care for all Humana Medicare Advantage members in Alabama. "UAB is well-respected and well-known for providing quality healthcare to its patients," said Matt Berger, President of Humana's Gulf South Region. "We are pleased to be able to offer all of our Humana Medicare Advantage members in Alabama an additional option for high quality healthcare as we help our members achieve and maintain their best health." The agreement took effect earlier this year.

10:46 EDT Barrick Gold trading resumes

10:42 EDT Spring Valley Acquisition Corp trading resumes

10:39 EDT Grupo Aeroportuario trading resumes

10:29 EDT Abbott trading resumes

10:21 EDT Chipotle trading resumes

10:16 EDT Cosan SA trading resumes

10:15 EDT Bank of Montreal trading resumes

10:12 EDT Santander Chile trading resumes

10:09 EDT Bank of Montreal trading halted, volatility trading pause

10:07 EDT Santander Chile trading halted, volatility trading pause

10:06 EDT Freedom Holding names Jason Kerr as chief legal officer - Freedom Holding announced the addition of new members to its board of directors and the creation of a chief legal officer position, effective May 28, 2024. Appointees include an employee director and two independent directors, all with a focus on supporting the continued enhancement of corporate governance, enterprise risk management and compliance. "It is with great pleasure that we welcome the appointments of Dr. Kairat Kelimbetov, and Messrs. Andrew Gamble and Philippe Vogeleer to the Freedom Holding Corp. board of directors," commented Timur Turlov, the chairman of the board of directors and CEO of the company. "I am also pleased to announce the creation of a CLO position for the Company. This new role is designed to assist us in establishing a unified legal structure across the enterprise and improve the coordination of the multi-jurisdictional legal affairs of the Company. Working with local legal teams, the CLO will occupy a vital role for the Company as we continue to develop our business segments internationally, and will aid in our regulatory compliance," commented Turlov. "Our former board member, Jason Kerr, has resigned his position as a Freedom Holding Corp. member of the board of directors and has agreed take on this role. We expect that his time as a Freedom Holding Corp. director, coupled with his experience as both in-house and external legal counsel, will serve him well in this capacity," he added.

10:06 EDT DESTINY TECH100 INC trading halted, volatility trading pause

10:05 EDT Novo Nordisk launches national Wevogy campaign - Novo Nordisk launched The Power of Wegovy, a new national campaign. The campaign aims to educate on the clinical data of Wegovy 2.4 mg injection and reflect the collective empowerment people living with obesity can feel when they don't have to manage their weight alone. "Diverse representation in health care campaigns can play a significant role in patients feeling seen, heard and understood, especially in a stigmatized space like obesity, which we've been engaged in for more than two decades," said Tejal Vishalpura, Senior Vice President, Commercial Strategy and Marketing for Novo Nordisk. "The Power of Wegovy is committed to representing a cross section of unique perspectives at this cultural inflection point in society, especially when the connection between obesity, cardiovascular risk, and the importance of patient-centered care is so much a part of the public discourse."

10:05 EDT KKR Real Estate Finance trading resumes

10:04 EDT American Assets Trust trading resumes

10:03 EDT Pitney Bowes opens presort services operating center serving St. Louis market - Pitney Bowes announced the opening of a new 45,000 square foot Presort Services operating center serving the St. Louis, MO market. The new highly automated facility, located at 13955 Riverport Place, Maryland Heights, MO processed nearly 100,000 pieces of mail on its inaugural day, with volumes steadily increasing throughout this summer. Currently, the site processes up to 1.2 million mail pieces a day.

10:02 EDT GSK falls -7.5% - GSK is down -7.5%, or -$3.35 to $41.41.

10:01 EDT Knot Offshore Partners rises 14.0% - Knot Offshore Partners is up 14.0%, or 88c to $7.18.

10:00 EDT Model N trading halted, volatility trading pause

10:00 EDT Apollo Commercial trading halted, volatility trading pause

10:00 EDT GameStop rises 40.8% - GameStop is up 40.8%, or $9.43 to $32.57.

09:58 EDT Mazda reports May North America sales up 6.9% y/y to 35,562 vehicles - Mazda North American Operations reported total May sales of 35,562 vehicles, an increase of 6.9% compared to May 2023. Year-to-date sales totaled 166,790 vehicles sold; an increase of 8.3% compared to the same time last year. With 26 selling days in May, compared to 25 the year prior, the company posted an increase of 2.8% on a Daily Selling Rate basis.

09:56 EDT Barrick Gold trading halted, volatility trading pause

09:53 EDT GREENWAVE TECHNOLOGY SOLUTIONS INC trading resumes

09:52 EDT MarineMax rises 17.8% - MarineMax is up 17.8%, or $5.08 to $33.56.

09:51 EDT AMC Entertainment rises 18.2% - AMC Entertainment is up 18.2%, or 79c to $5.12.

09:50 EDT Trinity Industries trading resumes

09:49 EDT Essex Property Trust trading halted, volatility trading pause

09:48 EDT Franco-Nevada trading halted, volatility trading pause

09:48 EDT GSK falls -7.8% - GSK is down -7.8%, or -$3.49 to $41.28.

09:46 EDT Horace Mann trading halted, volatility trading pause

09:45 EDT GM promotes Baris Cetinok, Dave Richardson to head software and services - General Motors is promoting Baris Cetinok and Dave Richardson to head its software and services organization as the company advances in electric, autonomous and connected vehicles. Since joining GM in September 2023, Cetinok and Richardson have played significant roles in building the vehicle operating and digital systems, enhancing quality testing and validation processes, and laying the foundation for software to become a central component of GM's customer experience. As senior vice president of software and services product management, program management, and design, Cetinok will oversee the teams responsible for the company's software roadmap design and the process for software program development, launch, and continual improvement. As senior vice president of software and services engineering, Richardson is expanding his current role to lead all of software engineering inclusive of areas like embedded platforms, digital products, commercial solutions, and advanced driver-assistance systems, or ADAS. Both will work in close collaboration with GM's vehicle design and hardware engineering organizations. The former technology executives take over for Mike Abbott, who left GM in March due to health reasons. They will be based out of the new GM Mountain View Technical Center in California.

09:44 EDT Xperi Corp trading resumes

09:42 EDT Plutonian Acquisition Corp trading resumes

09:42 EDT Knightscope partners with EnGoPlanet to jointly develop K1 Super Tower - Knightscope announces a partnership with EnGoPlanet, a Houston-based innovative solar street lighting company, to jointly develop the Knightscope K1 Super Tower. Knightscope first introduced the concept of the K1ST during the Company's Innovation Week earlier this year. The K1ST is a 20 ft. tall, solar-powered street light that incorporates a blue-light strobe, emergency communications, 360-degree ultra-HD video, Automated Gunshot Detection, Automated License Plate Recognition, a mass-notification speaker and an interactive display designed to make sustainable infrastructure and public safety accessible to everyone.

09:40 EDT Volaris trading resumes

09:39 EDT Xperi Corp trading halted, volatility trading pause

09:38 EDT Kintara Therapeutics, TuHURA Biosciences announces results from Phase 1b trial - TuHURA Biosciences and Kintara Therapeutics announced results from the primary analysis of TuHURA's completed Phase 1b trial evaluating IFx-2.0 among patients with advanced or metastatic MCC or cSCC who exhibited primary resistance to immune checkpoint inhibitor therapy. The abstract titled, "Phase 1b trial of IFx-Hu2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma," was presented by Andrew Brohl, MD, H. Lee Moffitt Cancer Center and Research Institute, in a poster presentation as part of the Melanoma/Skin Cancers session held at the 2024 ASCO Annual Meeting in Chicago, IL. The group that was of most interest were the seven patients with ICI naive, advanced MCC, who, prior to IFx-2.0 treatment, received no subsequent systemic or investigational therapies that may confound the ability to determine IFx-2.0's contribution to overcoming primary resistance to ICI therapy. Five of these 7 patients progressed within 3.8 months while receiving single agent anti-PD(L)-1 therapy. IFx-2.0 was administered as the immediate post ICI therapy. Following IFx-2.0 treatment, patients were rechallenged with an anti-PD(L)-1 agent. Four of the 5 patients achieved a durable objective response lasting, on average, 25 months, with 2 responses ongoing at 19 and 23 months. The remaining 2 of 7 patients, after progressing on anti-PD-1 therapy, also received and progressed on combination anti-PD1/anti-CTLA4 therapy prior to IFx-2.0 treatment. Following IFx-2.0, 1 patient achieved a PR, ongoing at 6 months following rechallenge with single agent anti-PD-1 rechallenge. The promising efficacy signal demonstrated in the Phase 1b study showing the potential for IFx-2.0 to overcome primary resistance to anti-PD(L)-1 therapy formed the rationale for TuHURA's planned Phase 3 registration-directed clinical trial. The Phase 3 trial will examine IFx-2.0 as an adjunctive therapy with Keytruda to improve tumor overall response rates when compared to Keytruda plus placebo in first line treatment of ICI naive patients with advanced or metastatic MCC. This Phase 3 trial is expected to begin enrollment in 2H 2024 under the FDA's Accelerated Approval Pathway. TuHURA's IFx-2.0 personalized cancer vaccine product involves the injection into a patient's tumor of a small amount of pDNA that is designed to encode for an immunogenic bacterial protein that gets expressed on the surface of the patient's tumor so that the surface of the tumor looks like a bacterium. By making the surface of a tumor look like a bacterium, IFx-2.0 is designed to use each patient's tumor itself as the source of foreign neoantigens to prime and initiate a patient's innate immune response against the tumor irrespective of whether the tumor escaped immune recognition prior to IFx-2.0 administration. In doing so, IFx-2.0 is designed to harness the power of the patient's innate immune response, which has evolved over time to be conserved to detect foreign pathogens like bacterial proteins. The primary objective of the Phase 1b study was to establish safety and feasibility of repeated administrations of IFx-2.0. The study met its primary safety objective: greater than or equal to80% completion of planned study therapy was predefined as a successful feasibility outcome. Given the proposed potential for immune priming effects of IFx-2.0, researchers performed an unplanned exploratory analysis of post-protocol treatment efficacy to evaluate response to ICI rechallenge. As reported at ASCO, following completion of protocol directed therapy, 11 patients with MCC and 6 patients with cSCC who, prior to study entry, failed anti-PD(L)1 or anti-PD-1/CTLA-4 therapy, were re-treated with anti-PD(L)1 monotherapy or combination therapy as the immediate IFx-2.0 post-protocol therapy: pembrolizumab, nivolumab + ipilimumab, or avelumab in MCC and cemiplimab in cSCC. The study concluded that IFx-Hu2.0 is safe and well tolerated at weekly dosing repeated up to 3 weeks. In an exploratory post-hoc analysis, 7 of 11 MCC patients treated with standard of care ICI agents immediately following protocol therapy experienced durable disease control despite prior failure of this same drug class prior to protocol enrollment, suggesting an "immune priming" effect of study therapy. Based on this promising efficacy signal, a randomized study of pembrolizumab +/- IFx-Hu2.0 is planned in the advanced MCC 1st line setting.

09:36 EDT GameStop trading resumes

09:35 EDT Global Partners trading halted, volatility trading pause

09:34 EDT Ault Disruptive Technologies Corp trading halted, volatility trading pause

09:33 EDT Monogram Technologies to host investor, analyst day - Monogram Technologies will host an investor and analyst day on Thursday, June 20th, 2024, from 9:00 a.m. CDT to 1:00 p.m. CDT at its cadaver lab and headquarters in Austin, Texas. Monogram Chief Executive Officer Ben Sexson, Founder & Chief Medical Officer Dr. Douglas Unis, Chief Technology Officer Dr. Kamran Shamaei, and Chief Financial Officer Noel Knape will be joined by other senior management team members to provide an overview of the company's work to develop a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, Artificial Intelligence, and next-generation robotics. Monogram is pushing hard on its commercial timeline, anticipating that Verification and Validation testing of its mBos TKA System will be largely complete in Q2 of 2024, with an anticipated 510(k) submission to follow in the second half of 2024. Monogram has also engaged a Contract Research Organization to oversee mBos robot clinical trial activities Outside the U.S. and received feedback from the U.S. Food and Drug Administration for verification test protocols and proposed clinical trial protocol on an OUS target population. "We very much look forward to hosting this event and maximizing transparency as much as possible," said CEO Ben Sexson. "Given the valuable insights gained from ongoing demonstrations to our current and potential tier-1 partners, we are aiming to expand our outreach to engage a larger audience." Immediately following the presentation and Q&A session, attendees will have the opportunity to tour Monogram's headquarters and cadaver lab. Investors and analysts who attend the tour will see a product demonstration of the mBos Robotic Surgical System, a game-changing innovation in robotic orthopedics that aims to help advance the standard of care in orthopedic medicine. The mBos precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants, which combine mVision AI and novel navigation methods.

09:32 EDT Plutonian Acquisition Corp trading halted, volatility trading pause

09:31 EDT CXApp files Q1 10Q on May 31 - CXApp announced that it filed its 10Q for Q1'2024 on May 31st,2024. The Company is now in full compliance as regards to regulatory filings and within the requisite Nasdaq timelines. The delay in the 10Q filing was because of the initial delay in the filing of the yearly 10K as the Company had undergone a business combination in 2023. Khurram Sheikh, Chairman and CEO of CXApp Inc, expressed confidence in the Company's performance: "We are happy to share our 10K and 10Q filings where we have made significant achievements including increased ARR and strong balance sheet giving confidence to our customers, partners and stakeholders. We continue to make great progress in shaping the future of work with our record NRR rate this quarter following our record ARR growth in 2023. Our existing customers have reposed confidence in the CXAI technology platform and our roadmap. We are solving real problems in the work environment for them, and they are now planning to scale up with our AI-first solutions across their enterprise footprint".

09:30 EDT Vision Marine Technologies files fifth patent on vehicle control unit apparatus - Vision Marine Technologies announced the filing of its fifth patent, focusing on a vehicle control unit apparatus that maximizes the functionality of an intelligent electric marine powertrain. This latest patent filing underscores Vision Marines' innovative approach within the maritime sector. The E-Motion VCU is the culmination of over five years of dedicated research and development in embedded software design. Developed in-house for the E-Motion 180E powertrain, the VCU controls and monitors all functions and readings of the high and low voltage systems, actively surveying status, connection integrity, and critical readings from over 12 components and 40 sensors through advanced communication authentication and processing.

09:27 EDT CalAmp enters restructuring support agreement with Lynrock - CalAmp announced that it has entered into a Restructuring Support Agreement with its principal secured lender, Lynrock Lake Master Fund, who will become the principal equity owner of CalAmp and take the Company private. In a strategic move that strengthens its financial position, CalAmp intends to exchange the approximately $229 million of Convertible Senior Secured Notes held by Lynrock into equity interests in the reorganized company. During the financial restructuring, CalAmp's U.S. and international operations will continue without disruption, and partners will be paid in the ordinary course of business. To most efficiently complete the go-private transaction, CalAmp has voluntarily initiated proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. CalAmp enters this process with the strong support of Lynrock who has conveyed confidence in the Company's long-term strategy and future growth prospects. Importantly, the RSA provides a roadmap for the Company to quickly navigate through this process following court approval of its prepackaged restructuring plan. CalAmp is dedicated to emerging promptly from this process with a healthy balance sheet and strong cash flow generation that will enable it to be a stronger business partner.

09:25 EDT CalAmp reports Chapter 11 bankruptcy filing, restructuring support agreement - On May 31, CalAmp Corp. and its wholly-owned subsidiaries, CalAmp Wireless Networks Corporation, LoJack Global LLC and Synovia Solutions LLC, entered into a Restructuring Support Agreement with Lynrock Lake Master Fund LP, as lender under the Secured Term Loan Facility, and the holder of Secured Notes Claims. The RSA contemplates a financial restructuring of the company's debts by, among other things, (i) amending and restating the Secured Term Loan Facility with a lower interest rate and longer maturity date, (ii) converting the approximately $229M of Convertible Senior Secured Notes held by Lynrock to equity, and (iii) paying allowed unsecured claims in full in cash or such other treatment so as to render such claims unimpaired. The company will seek to effectuate the RSA through a joint prepackaged chapter 11 plan of reorganization, pursuant to which, among other things, the company will become a private company. The Plan further contemplates that existing equity interests of CalAmp, including warrants, options, restricted stock units and preferred stock units, will be cancelled. On June 3, CalAmp and its wholly-owned subsidiaries, CalAmp Wireless Networks Corporation, LoJack Global LLC and Synovia Solutions LLC, filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware. "The Debtors continue to operate their businesses as 'debtors in possession' under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court. The Debtors sought approval of a variety of "first day" motions containing customary relief intended to assure the Company's ability to continue its ordinary course operations and make a smooth transition into Chapter 11. The Company will seek an order regarding the Company's common stock, par value $0.01 per share. The NOL Order, if approved by the Bankruptcy Court, will be designed to assist the Debtors in preserving certain of their tax attributes by establishing, among other things, procedures that certain stockholders and potential stockholders must comply with regarding transfers of the Common Stock, as well as certain obligations with respect to notifying the Debtors of current stock ownership. The Debtors will seek prompt confirmation of the Plan and to emerge from the Chapter 11 proceeding a significantly de-levered company," a regulatory filing stated. Reference Link

09:22 EDT CNS Pharmaceuticals announces 1-for-50 reverse stock split - CNS Pharmaceuticals announced a 1-for-50 reverse split of its common stock, effective at 4:01 PM ET on June 4, 2024. Beginning on June 5, 2024, the Company's common stock will continue to trade on The Nasdaq Capital Market on a split adjusted basis under the trading symbol "CNSP", but will trade under the following new CUSIP number: 18978H300. The reverse stock split is primarily intended to increase the Company's per share trading price and bring the Company into compliance with the Nasdaq's listing requirement regarding minimum share price.

09:21 EDT Bion Environmental CEO Bill O'Neill resigns - Bion Environmental Technologies announced several leadership changes as it refocuses on execution and commencing project development. Bion has accepted the resignation of Bill O'Neill, its CEO, which became effective on June 1. Mr. O'Neill is departing to pursue other interests. He will work with Bion management through the end of June to help ensure a smooth transition. Mr. O'Neill's resignation from Bion's Board of Directors was also accepted. Greg Schoener has assumed the role of COO on an interim basis, effective June 1. He has also joined Bion's Board of Directors. Mr. Schoener is a successful business owner and operator, serving the construction industry in Houston, Texas. He brings broad business management experience, with an emphasis on mission-focused execution and accountability. Greg has been a Bion shareholder since late-2020. Craig Scott has joined the Company's Board of Directors, effective June 1. Craig has served Bion in several senior positions, dating back to 1996. Along with his current duties, Mr. Scott will assume a broader management role for Bion, including business development. Mark Smith, Chairman of the Board of Directors and Bion's President and counsel, was slated to retire at the end of June 2024. Mr. Smith has agreed to continue to perform his duties for the time being to assist Bion in its transition. The remainder of Bion's Board members, Bill Rupp, Salvatore Zizza, Ed Schafer, and Jon Northrop will also continue in their roles. More additions to the team and Board can be expected.

09:19 EDT Ocular Therapeutix to eliminate 13% of company's workforce - In a regulatory filing, Ocular Therapeutix disclosed that on May 29, the board of directors of the company approved a strategic reduction in force to eliminate 37 full-time employees of the company, primarily in research and development and technical operations and representing approximately 13% of the company's workforce, as part of an initiative to prioritize company resources on the clinical development of AXPAXLI, also known as OTX-TKI, for the treatment of wet age-related macular degeneration. The company currently expects to substantially complete the reduction in force and to record the related restructuring charges in the second quarter of 2024. The company anticipates incurring total restructuring costs of approximately $1.0M-$2.0M, which includes garden leave, severance benefits and related costs and which are expected to result in cash expenditures during the second and third quarters of 2024. "The company is continuing to review its business plan and the potential impact of the reduction in force and is unable to estimate any additional restructuring costs or charges at this time," the filing stated. Reference Link

09:18 EDT Google Cloud expands partnership with Workday - Google Cloud (GOOGL) announced an expanded partnership with Workday (WDAY) that will bring new generative AI capabilities to enhance how customers build and manage apps on Workday. Through the partnership, Workday will use Gemini models and Vertex AI to enable gen AI capabilities within Workday Extend, helping customers optimize business performance, generate powerful business insights, and expedite transaction and closing processes.

09:17 EDT Cohen & Steers, DLC Management acquire open-air shopping center complex - Cohen & Steers announced that an affiliate of Cohen & Steers Capital Management and DLC Management, an owner and operator of open-air shopping centers in the U.S., have jointly acquired a two-property open-air shopping center complex in Fayetteville, Arkansas. The acquisition is comprised of two centers, Spring Creek Centre and Steele Crossing, and encompasses 403,000 square feet of owned retail space. The centers are 95% occupied by tenants.

09:16 EDT SunPower announces $50M draw on second lien term loan - SunPower announced it has drawn upon the $50 million second tranche of the $175 million second lien term loan from Sol Holding that it announced in February 2024. Sol Holding, which is owned jointly by affiliates of TotalEnergies SE and Global Infrastructure Partners, is the majority owner of SunPower's common stock. "Today's announcement demonstrates the continued support of our majority shareholders in the long-term value proposition of residential solar and SunPower's commitment to operating a financially sound business," said Tom Werner, Principal Executive Officer at SunPower. "In addition to this funding, in recent months, we have worked to reduce overall costs and increase the proportion of our costs that vary with changes in volume as we aim to build a more resilient business that can deliver consistent positive free cash flow in the future."

09:15 EDT Serve Robotics integrates DriveU.auto's connectivity platform - DriveU.auto and Serve Robotics announced the deployment of DriveU.auto's connectivity platform on Serve's commercially-deployed robotic fleet. Serve will leverage DriveU's platform to enhance the performance of remote monitoring of its autonomous delivery robots-adding to the suite of tools Serve utilizes as it works to deploy up to 2,000 robots on the Uber Eats platform. "In order to rapidly scale to thousands of robots, Serve needs to leverage the capabilities of world-class technology partners like DriveU.auto," said Dmitry Demeshchuk, Co-founder and Vice President of Software Engineering at Serve. "DriveU's connectivity platform will help us improve the resilience and performance of our fleet, unlock operational efficiencies, and realize economies of scale as we pursue mass market autonomous delivery."

09:14 EDT Modular Medical announces addition to Russell Microcap Index - Modular Medical announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024.

09:13 EDT SaverOne 2014 to establish company dedicated to Vulnerable Road User solution - SaverOne 2014 will establish a new company dedicated to its Vulnerable Road User solution which leverages its RF Advanced Driver Assistance System sensor technology. This strategic move follows the conclusion of a comprehensive project completed by a leading global consultancy firm, announced in March, which analyzed the addressable market potential, as well as the initial interest from OEMs. The consultancy firm's analysis projects a market potential annually of $1.5 billion by 2035, for SaverOne's RF ADAS technology, which enhances vehicle safety by detecting VRUs such as pedestrians and cyclists even in non-line-of-sight scenarios, a problem that no existing sensor, that, for example, camera, radar or LIDAR, can currently solve. Recently, SaverOne announced a purchase order from leading European OEM, IVECO, for a paid proof-of-concept order of its VRU solution. Following these positive developments, SaverOne has decided to establish a subsidiary company specifically focused on advancing the development, commercialization, and the broad adoption of the VRU solution. Furthermore, SaverOne is actively approaching potential investors and strategic partners to partner with and support the new company.

09:12 EDT Valuence Merger Corp. I announces adjournment of shareholder meeting - Valuence Merger Corp. I has adjourned the extraordinary general meeting seeking shareholder approval of an extension of the time that it has to consummate an initial business combination. The Meeting will reconvene at 5:00 p.m. Eastern Time, on Monday, June 3, 2024. The Meeting will still be held in person at the offices of White & Case LLP, 1221 Avenue of the Americas, New York, NY 10020. The purpose of the adjournment is to provide additional time for shareholders to withdraw any previously delivered demand for redemption of their shares.

09:11 EDT Hawkins completes acquisition of Intercoastal Trading assets - Hawkins has completed the acquisition of the assets of Intercoastal Trading, Inc. and its affiliated companies. Intercoastal Trading distributes water treatment chemicals and equipment for its customers in Maryland, Delaware, and Virginia. "As we continue to grow our water treatment business, Intercoastal Trading will accelerate our expansion in the heavily populated East Coast with its location within 200 miles of major population centers," said CEO Patrick H. Hawkins. "Intercoastal Trading has built a strong business that is well-connected with the local community, and we intend to maintain and expand those connections. We expect the acquisition of Intercostal Trading to be accretive to earnings per share this fiscal year and we expect that even after this acquisition, our first quarter balance sheet will remain strong, with an anticipated leverage ratio of approximately 1x EBITDA at quarter end. In addition, I am pleased to report that all four acquisitions we completed during fiscal 2024 are meeting or exceeding our business plans and the integrations are on track."

09:10 EDT Trex Company partners with Paragon Stairs for Trex Spiral Stairs - Trex Company announces a strategic new addition to its roster of licensed partners. The company has tapped Paragon Stairs, the largest producer of spiral stairs in the U.S., to be the exclusive supplier for its Trex Spiral Stairs collection.

09:09 EDT Getty Images named official photographer of 2024 Tribeca Festival - Getty Images has once again been named the Official Photographer of the Tribeca Festival, renewing a longstanding partnership with the foremost outlet for independent storytellers. For the fifteenth consecutive festival, Getty Images' entertainment photographers will capture high-quality, differentiated imagery throughout the Tribeca Festival in New York City. This includes all red carpet premieres, film screenings, sponsored activations and parties from over 100 feature films, often from exclusive positions not available from any other source.

09:07 EDT Adams Diversified Equity, Adams Natural Resources announce governance updates - Adams Diversified Equity Fund (ADX), and Adams Natural Resources Fund (PEO) announced that the Board of Directors of each Fund has unanimously approved several governance updates: election of a classified board structure and adoption of certain bylaws amendments. The Funds have each elected to be subject to Maryland Corporations Code Section 3-803, which provides for a classified board structure consisting of three director classes of three years each. These elections strengthen the stability of Fund oversight and operations, furthering each Fund's objectives and serving the long-term interests of shareholders and the Funds. The Funds also have approved bylaws amendments, including those related to director qualifications. The Funds' Boards of Directors approved these governance changes following an extensive review and evaluation of possible alternatives and enhancements designed to safeguard and advance the best interests of the Funds and their shareholders and to position the Funds to continue to seek to meet their investment objectives.

09:06 EDT Coveo Solutions chosen by Thalia - Coveo announced that Thalia has chosen Coveo to deliver AI search, recommendations and personalization on their commerce website.

09:05 EDT Netgear announces ITC judge rules TP-Link infringed its patents - Netgear reported that on May 30, Administrative Law Judge Doris Johnson Hines, or ALJ, of the U.S. International Trade Commission, or ITC, issued an Initial Determination finding that China-based TP-Link violated federal law by importing and selling in the United States its multi-band Wi-Fi devices, routers and mesh networking devices. The ALJ's Initial Determination comes in response to a complaint filed with the ITC by Netgear in April 2023, alleging that TP-Link's products infringe certain of Netgear's patents. The ITC instituted an investigation into Netgear's allegations and assigned the investigation to an ALJ on May 8, 2023. In concluding that TP-Link violated Section 337 of the Tariff Act of 1930, the ALJ determined that TP-Link's products infringe all the asserted claims of Netgear's U.S. Patent Nos. 7,936,714 and 10,681,698. In addition, the ALJ recommended that the ITC issue a Limited Exclusion Order to U.S. Customs and Border Protection to prevent further importation of TP-Link's infringing products, as well as a Cease and Desist Order to TP-Link prohibiting further importation, sale, and marketing of TP-Link's infringing products. The initial determination is subject to review by the full Commission, which is scheduled to issue its Final Determination by October 3.

09:04 EDT Longeveron launches contract development, manufacturing business - Longeveron announced the launch of its contract development and manufacturing business at the Company's 15,000 square feet Good Manufacturing Practice facility. This facility contains 3,000 square feet of cleanroom space, including eight ISO 7 cleanrooms and ancillary areas, as well as 1,150 square feet of process development, quality control and warehousing space. The Company also announced the initiation of work under its first manufacturing services contract with Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells.

08:58 EDT Politan, an 8% holder of Masimo, files preliminary proxy statement - Politan Capital Management an 8.9% shareholder of Masimo Corporation announced that it has filed a preliminary proxy statement with the U.S. Securities and Exchange Commission in connection with its nomination of two independent candidates for election to the Masimo Board of Directors at the upcoming 2024 Annual Meeting of Stockholders which is currently scheduled for July 25th. The record date for the Annual Meeting is set for June 13th. Politan also commented on the announcement that Christopher Chavez has been nominated by the Company to run for election at the Annual Meeting. Quentin Koffey, Managing Partner and Chief Investment Officer of Politan, and a current director on the Masimo Board, stated: "This recent announcement further demonstrates Mr. Kiani and his selected directors' resistance to independent oversight. Mr. Kiani and Mr. Chavez have a relationship that goes back more than 20 years. The Nominating, Compliance and Corporate Governance committee never recommended him, never met to consider other candidates, and never used a search firm in his selection. Just like every single director currently on the Board, except for those nominated by Politan, Mr. Chavez was not chosen through an objective process utilizing an independent search firm - he was chosen by Mr. Kiani. As leading proxy advisory firm Institutional Shareholder Services noted in its report last year, '...the board has effectively been assembled by the CEO, which undermines independence, and creates uncertainty about where loyalties lie.' This announcement is more of the same. Further, the repeated claim that Politan refuses to engage in settlement discussions is false. We have offered several compromises that would avoid a contested election and allow Mr. Kiani to remain on the Board. Our nominees - Dr. Darlene Solomon and William Jellison - would bring sorely needed financial, technical, and corporate-spinoff/separation expertise to the Masimo Board. They are also both unquestionably independent, as no one on Masimo's Board or at Politan has any pre-existing relationship with either of them and Politan used a nationally recognized search firm to identify and contact them. We encourage shareholders to focus on the need for a truly independent Board overseeing the critical decisions that face Masimo. We look forward to engaging further with our fellow shareholders to ensure this happens."

08:54 EDT Nexalin Technology says FDA reaches consensus on design for HALO studies - Nexalin Technology announces that the U.S. Food and Drug Administration has provided feedback and reached consensus on the design for its planned clinical studies in anxiety and insomnia for its new Gen-3 HALO Clarity, a non-invasive, Deep Intracranial Frequency Stimulation headset device designed to address the global mental health epidemic. After the studies are completed and evaluated, Nexalin plans to submit a De Novo request application for the HALO to the FDA. The De Novo request provides a marketing pathway to classify new novel medical devices. The initial pilot and pivotal studies for anxiety and insomnia are expected to commence in the third quarter of 2024. Each of the pivotal studies will include 75 patients receiving active treatment and 75 patients receiving sham treatment and are intended to evaluate HALO's ability to reduce symptoms of anxiety and insomnia, respectively. These two studies are intended to build on the positive results of prior published clinical studies evaluating Nexalin's Gen-3 HALO utilizing the new advanced DIFS waveform.

08:52 EDT Lixte Biotechnology appoints Jan Schellens as CMO - LIXTE Biotechnology announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer. Schellens brings to LIXTE more than 25 years of clinical experience as a medical oncologist, pharmacologist and clinical pharmacologist, including more than two decades developing and bringing new drugs to market. He assumes the CMO role at LIXTE effective August 1, 2024, succeeding James S. Miser, M.D., who is leaving the Company after serving in this capacity since 2020.

08:51 EDT Tian Ruixiang regains compliance with Nasdaq minimum bid price rule - TIAN RUIXIANG announced that the Company received a written notification from the Nasdaq Stock Market on May 29, 2024, informing the Company that it has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). According to the Notification Letter, as of May 28, 2024, the Company has maintained a closing bid price of $1.00 per share or greater for ten consecutive business days. In addition, the Company received a letter from Nasdaq on May 29, 2024, granting the Company an extension until August 15, 2024 to regain compliance with Nasdaq's filing requirements set forth in Listing Rule 5250(c)(1). As previously reported, the Company received a deficiency notice from Nasdaq on March 20, 2024, due to the delay in filing its Annual Report on Form 20-F for the fiscal year ended October 31, 2023. To rectify this situation, the Company has been working diligently with its auditors and anticipates that it will file the Annual Report before August 15, 2024, however, there is no assurance that it will be able to do so. If the Company fails to file Form 20-F by August 15, 2024, the Company will be subject to delisting. The Extension Notice does not affect the Company's business operations, its U.S. Securities and Exchange Commission reporting requirements, or its contractual obligations.

08:50 EDT Lantheus announces aPROMISE available on syngo.via platform - Lantheus Holdings announced that aPROMISE, its AI-enabled FDA-cleared medical device software, is now available on the syngo.via platform, from Siemens Healthineers, one of the leading workstation systems. Siemens Healthineers will be demonstrating the integrated solution at the upcoming annual Society of Nuclear Medicine and Molecular Imaging annual meeting in Toronto June 8-11, 2024. aPROMISE is a deep learning-enabled, FDA-cleared medical device software that provides quantitative total disease burden on PSMA PET/CT images, including those obtained using PYLARIFY PET/CT. In planned prospective and independent validation studies, aPROMISE has demonstrated rapid lesion detection and standardized quantitative tumor burden biomarkers in PSMA PET/CT imaging. Recent clinical studies have shown that total quantitative burden with aPROMISE supports patient selection for PSMA radioligand therapy and automates monitoring response over time.

08:48 EDT Molecular Templates provides update on clinical-stage programs - Eric Poma, PhD., Chief Executive and Chief Scientific Officer of MTEM, stated, "ETBs are a potentially powerful therapeutic approach to selectively depleting immunosuppressive cells in oncology or eliminating self-reacting immune cells in severe immune-mediated diseases. The monotherapy activity we see with MT-6402 in relapsed/refractory solid tumor patients, and the clinical and ex vivo depletion of CD38+ immune cells seen with MT-0169 at well-tolerated doses underscore the potential of this platform across multiple diseases." Company Pipeline Highlights: MT-6402: Promising Single-Agent Activity: MT-6402 has shown monotherapy activity in heavily pre-treated patients who had previously progressed or were refractory to immuno-oncology therapy. Head and Neck Cancer Responses: MTEM had previously reported that nine patients with head and neck squamous cell carcinoma had been treated in the Phase 1 dose escalation. Two heavily pre-treated patients with low PD-L1 expressing squamous cell carcinoma of the head and neck had achieved partial responses with MT-6402 monotherapy. These patients remain in response and in good clinical condition, continuing treatment in cycles 21 and 12, respectively. In addition, four of the HNSCC patients treated with MT-6402 had stable disease with two showing tumor reduction. All patients with tumor responses or tumor reduction had low PD-L1 expression. New Lung Cancer Response: An unconfirmed partial response was observed in a non-small cell lung cancer patient with high PD-L1 expression in the Phase 1b monotherapy dose expansion study in solid tumor patients with high PD-L1 tumor expression. The patient achieved a partial response at the end of cycle 8 following sustained tumor reduction in prior assessments. A PET scan in cycle 8 showed no indications of active metastatic disease. This patient had previously progressed on chemotherapy, targeted therapy, and checkpoint therapy, including progression within six months on pembrolizumab + ramucirumab, before enrolling in the study. Three other NSCLC patients with high PD-L1 expression have been dosed in the Phase 1b expansion study. Two of these patients had progressive disease and one passed away from COVID and was not evaluable. Favorable Safety Profile: To date, MT-6402 appears to be generally well-tolerated, with no drug-related adverse events exceeding grade 3. Ongoing Enrollment: MTEM continues to enroll HNSCC patients with low PD-L1 expression and patients with solid tumors with high PD-L1 expression. MT-0169: Clinical proof-of-concept supports the elimination of CD38+ cells in immune-mediated disease. Recent clinical data with CD38 antibodies have demonstrated the therapeutic potential of CD38+ immune cell clearance in several immune-mediated diseases. Despite these promising early data, a more potent mechanism of CD38+ immune cell depletion may provide greater clinical benefit. Potent and unique mechanism of action. MT-0169 is designed to destroy CD38+ tumor or immune cells through internalization of CD38 and cell destruction via a novel mechanism of action. In ex vivo cell kill assays, MT-0169 shows potency against plasma cells with IC50 activity in the picomolar or femtomolar range. Plasma cells are exceptionally sensitive to ER stress, making them uniquely susceptible to the MT-0169 mechanism of action. MT-0169 also shows potent activity against T-cells that express low levels of CD38. HLA-DR CD38+ T-cells have been implicated in many immune-mediated diseases. Overcoming antibody resistance. The unique mechanism of action of MT-0169 and its lack of an Fc domain may avoid resistance mechanisms seen with CD38 antibodies like receptor downregulation or trogocytosis while allowing for combination approaches with FcRn-targeting therapies. Clinical proof-of-concept with MT-0169. MTEM's Phase 1 study in patients with relapsed or refractory multiple myeloma dosed at 5, 10, or 15 mcg/kg showed potent depletion of CD38+ immune cells with no drug-related adverse events of grade 3 or higher noted in these patients. Planned clinical development with MT-0169. MTEM will continue to develop MT-0169 in hematology and is evaluating the potential of MT-0169 in severe immune-mediated diseases. MT-8421: Tumor microenvironment dismantling. MT-8421 is designed to potently destroy CTLA4+ Tregs, alleviating immunosuppression in the tumor microenvironment. Pharmacodynamic effects observed early Phase 1 dose escalation. Three patients were dosed in the first cohort of the Phase 1 study at 32 mcg/kg. No drug-related adverse events of grade 3 or higher were observed. One patient had disease progression at the end of cycle 2. Two patients have stable disease and remain on study at cycle 8 and cycle 7, respectively. The two patients in stable disease showed peripheral depletion of Tregs and significant elevations in IL-2 while on therapy. One of the patients has a notable decrease in ctDNA. Dose escalation continues. Enrollment is on-going in the second cohort of 48 mcg/kg for the Phase 1 study of MT-8421.

08:44 EDT Coherent appoints Jim Anderson as CEO - Coherent (COHR) announced that following a comprehensive search, its Board of Directors has appointed Jim Anderson as the Company's new CEO, effective today. Mr. Anderson also joins the Company's Board of Directors. Anderson joins Coherent from Lattice Semiconductors (LSCC), where he was President, CEO, and a member of its Board of Directors.

08:42 EDT MDA Space awarded contract for Square Kilometre Array project - MDA Space announced it has been awarded a contract by the National Research Council of Canada, NRC, to support the development, construction and integration of game-changing radio telescope technology for the Square Kilometre Array Observatory, SKAO, an international space exploration and astronomy project that seeks to further our understanding of the formation and evolution of the universe. "MDA Space is proud to be contributing to this important international scientific endeavour that will listen and look out into space to expand our understanding of the universe," said Mike Greenley, CEO of MDA Space. "Projects of this size, scope and significance present a unique opportunity to showcase the expertise and innovation of Canadian astronomers, astrophysicists and industry while driving new discoveries and advancements in science and technology."

08:41 EDT NKGen Biotech to present updated Phase 1 data on SNK02 - NKGen Biotech announced that Paul Y. Song, MD, Chairman and CEO of NKGen Biotech, will present details on their cryopreserved allogeneic NK cell therapy platform as well as updated Phase 1 data on its use in solid tumors without lymphodepletion at the 6th Annual Allogeneic Cell Therapies Summit to be held in Boston, MA, from June 10-12, 2024. Song's presentation will detail the Company's novel allogeneic blood-derived NK cell therapy commercial manufacturing and cryopreservation process, as well provide an update on their initial Phase 1 results using SNK02 to treat patients with advanced refractory solid tumors. Furthermore, Dr. Song will explore the potential benefits of eliminating pre-treatment lymphodepletion in patients undergoing SNK02 therapy, aiming to safeguard immune function and aid in recovery. Avoiding lymphodepletion before administering cancer treatment can provide many benefits including reduced toxicity, preservation of immune function, and potentially enhancing treatment efficacy. The presentation will also include a discussion on an unexpected discovery from the SNK02 Phase 1 trial, hinting at its possible applicability as a treatment for patients beyond cancer.

08:41 EDT German American reports sale of asstes of GAI to Hilb Group for $40M - German American Bancorp announced and closed the sale of the assets of its wholly-owned subsidiary German American Insurance to Hilb Group, an industry-leading insurance broker. The all-cash transaction is for $40M, and creates a significant after-tax gain, net of transaction costs, of approximately $27M. The purchase price represents approximately four times 2023 GAI revenues and approximately 24 times 2023 GAI after-tax earnings. "Our decision to partner with Hilb Group for this transaction ensures the continued access to the best insurance products and services for our customers and provides a great new home for GAI's employees," said D. Neil Dauby, Chairman and CEO of German American Bancorp, Inc. "This sale allows us to realize significant value at an opportune time. The GAI team has done a tremendous job building the agency in the last 25 years, and we are confident the expanded access to products, services and expertise through Hilb Group will support a strong future for all." As part of the transaction, German American Insurance will continue to operate throughout southern Indiana and Kentucky under the name "German American Insurance - A Hilb Group Company" and will remain under the leadership of Diana Wilderman, President of German American Insurance. Piper Sandler & Co. served as financial advisor to German American and Dentons Bingham Greenebaum LLP served as legal counsel.

08:40 EDT Hertz announces appointment of Haralson as Chief Financial Officer - Hertz Global (HTZ) announced the appointment of Scott Haralson as Chief Financial Officer, joining the company by the end of June. Haralson will succeed Alexandra Brooks, who is leaving the Company to pursue other opportunities but will remain until the end of the month to ensure an orderly transition. Haralson is a seasoned executive and veteran of the transportation industry with over 25 years of leadership and corporate finance experience, having most recently served as Chief Financial Officer of Spirit Airlines (SAVE)

08:38 EDT Mainz Biomed presents data from pooled study at ASCO 2024 - Mainz Biomed presented pivotal data from its largest cohort to date during a poster presentation at the American Society of Clinical Oncology 2024 Annual Meeting in Chicago, Illinois, and online. This data combines results from the ColoFuture and eAArly DETECT studies including additional patients collected since the first reported study results, demonstrating the significance of its innovative screening approach. The combined analysis involves 690 clinical subjects from 30 specialized gastroenterology centers across Europe and the United States, including previously unexamined and unreported samples, highlighting the remarkable efficacy of Mainz Biomed's multimodal screening test. This test integrates the Fecal Immunochemical Test with proprietary mRNA biomarkers, complemented by an advanced AI and machine learning algorithm. This combination enables precise differentiation among colorectal cancer, advanced adenomas, non-advanced adenomas, and samples with no pathological findings. Key Findings Sensitivity for Colorectal Cancer: 92.3% Specificity: 90.1% Sensitivity for Advanced Precancerous Lesions: 82.2%; High-Grade Dysplasia Detection Rate: 95.8% This study highlighted the significant advantage of the multimodal screening test over existing methods, particularly in detecting advanced precancerous lesions. For example, the sensitivity for detecting high-grade dysplasia, which have an increased risk of turning into cancer, with the multimodal approach was 95.8%, significantly higher than other non-invasive tests currently available.

08:38 EDT Ecolab, Repligen announce commercial launch of DurA Cycle affinity resin - Ecolab (ECL) announced that its Purolite resin business, together with Repligen (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of Purolite's DurA Cycle, a protein A chromatography resin for large-scale purification processes. This new affinity resin is being introduced at the BIO International Convention being held June 3-6 in San Diego. This latest innovation marks a significant milestone in Purolite's long-term strategic partnership with Repligen, further solidifying Ecolab's dedication to driving advancements in the bioprocessing industry...Ralf Kuriyel, vice president of research & development at Repligen, emphasized the significance of the partnership, stating, "The bioprocessing industry is seeking partnerships that can effectively address the most complex challenges in biologic manufacturing. Our collaboration with Purolite, an Ecolab Company, advances industry progress by delivering cutting-edge solutions that meet these demands. Together, we are paving the way for the future of bioprocessing." ...The announcement of Purolite's latest resin follows news of its investment in a new bioprocessing production facility based in Landenberg, PA, which complements its UK-based facility, providing dual continent manufacturing capabilities to address growing customer demand.

08:37 EDT Alexandria Real Estate increases quarterly dividend 3c to $1.30 per share - Alexandria Real Estate Equities announced that its Board of Directors declared a quarterly cash dividend of $1.30 per common share for the second quarter of 2024. The dividend is payable on July 15, 2024 to stockholders of record on June 28, 2024. The common stock dividend for the 12 months ending June 30, 2024 of $5.08 per common share represents an increase of 24 cents, or 5 percent, over the 12 months ended June 30, 2023.

08:36 EDT Moderna, Merck announce 3-year data for mRNA-4157 in combination with Keytruda - Moderna (MRNA) and Merck (MRK) announced the first presentation of results from a planned analysis from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157, or V940, an investigational individualized neoantigen therapy, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, in patients with resected high-risk melanoma following complete resection. With a median follow-up of approximately three years, adjuvant treatment with mRNA-4157 in combination with KEYTRUDA continued to demonstrate a clinically meaningful and durable improvement in recurrence-free survival, or RFS, the primary endpoint of the study, reducing the risk of recurrence or death by 49% compared with KEYTRUDA alone. mRNA-4157 in combination with KEYTRUDA also continued to demonstrate a meaningful improvement in distant metastasis-free survival, or DMFS, a key secondary endpoint of the study, compared with KEYTRUDA alone, reducing the risk of developing distant metastasis or death by 62%. These data are being presented today during a rapid oral abstract session at the 2024 American Society of Clinical Oncology, or ASCO, Annual Meeting. With an additional year of planned follow-up, these data build on the earlier analysis of the primary and key secondary endpoints of the study, presented in 2023. The 2.5-year recurrence-free survival rate of mRNA-4157 in combination with KEYTRUDA was 74.8%, as compared to 55.6% for KEYTRUDA alone, with the benefit observed across exploratory subgroups. "We are encouraged by the latest results from the KEYNOTE-942/mRNA-4157-P201 study. These data highlight the sustained benefit in RFS and DMFS of mRNA-4157 as adjuvant treatment in combination with KEYTRUDA in people with resected high-risk melanoma. Importantly, this benefit was observed across various patient exploratory subgroups, reflecting the potential of mRNA-4157 for a broad range of these patients. These findings reinforce our commitment to advancing this innovative treatment in collaboration with Merck, and we are dedicated to harnessing mRNA technology to potentially transform cancer therapy and improve patient outcomes," said Kyle Holen, M.D., Moderna's Senior Vice President and Head of Development, Therapeutics and Oncology.

08:35 EDT Denali Therapeutics says FDA selects DNL126 for START Pilot Program - Denali Therapeutics announced that the U.S. Food and Drug Administration has selected DNL126 for participation in the Support for clinical Trials Advancing Rare disease Therapeutics Pilot Program. DNL126 is an investigational enzyme replacement therapy designed to cross the BBB for the potential treatment of MPS IIIA. The FDA announced the START Pilot Program on September 29, 2023, with the stated purpose to further accelerate the pace of development of novel drug and biological products that are intended to address an unmet medical need as a treatment for a rare disease. Selected participants of the START Pilot Program are provided opportunities to obtain frequent advice and engage in more rapid ad hoc communication with FDA review staff to address product-specific development issues. The START pilot and metrics are milestone driven and agreed upon by the FDA and sponsor. Initial selection for START planned to include up to six eligible programs from the FDA's Center for Biologics Evaluation and Research's Office of Therapeutic Products and Center for Drug Evaluation and Research's Office of New Drugs.Denali is conducting a Phase 1/2 study of DNL126 for children with MPS IIIA, which has generated high interest from the MPS IIIA community for whom there are no approved treatment options. As a selected START participant, Denali anticipates the increased level of engagement will facilitate alignment on the most efficient development path to ultimately support a marketing application for DNL126 in MPS IIIA. Denali is also developing tividenofusp alfa as a potential treatment for people living with MPS II and expects to complete enrollment of the Phase 2/3 COMPASS study this year. Given the advanced development stage of the program, Denali did not apply to START for tividenofusp alfa. The FDA granted Fast Track designation to tividenofusp alfa, which also facilitates increased communication and engagement with the FDA specific to this program.

08:34 EDT Zion Oil & Gas announces start of recompletion operations for MJ-01 Well - Zion Oil & Gas announces the start of recompletion operations for the MJ-01 well in Israel. Crews are mobilizing, and boots are officially on the ground, marking an exciting step forward in our journey towards Israel's onshore energy potential. "Operations have officially kicked off, and our crew is fully engaged in safety testing and moving the rig," said Zion Oil & Gas CEO, Rob Dunn. "We are ensuring all plans are followed to maximize the potential of the MJ-01 well."

08:30 EDT Evaxion Biotech presents immune data from ongoing Phase 2 trial of EVX-01 - Evaxion Biotech reported data from its ongoing Phase 2 study at the American Society of Clinical Oncology Annual Meeting 2024. The data demonstrated vaccine-induced immune response in metastatic melanoma patients treated with the Company's AI-Immunology designed personalized cancer vaccine, EVX-01, in combination with an anti-PD1 inhibitor. The EVX-01 vaccine targets neoantigens - antigenic sequences derived from cancer mutations - that are displayed on the surface of the cancer cells, allowing the immune system to recognize, attack and eliminate the malignant cells. Key EVX-01 Phase 2 study findings presented at the meeting: The EVX-01 vaccine induced specific and targeted immune responses, with 71% of the administered neoantigens eliciting a T-cell response; The neoantigen-reactive immune responses were mediated by both CD4+ and CD8+ T-cells; EVX-01 booster immunizations tended to increase the immune responses and did not impose any safety concerns; A statistically significant positive correlation between neoantigen quality, as predicted by AI-Immunology, and vaccine-induced immune response was demonstrated; The EVX-01 vaccine candidate was found to be well-tolerated, with only grade 1 and 2 adverse events; The data presented from the Phase 2 study currently confirm findings from the previous EVX-01 Phase 1 study, reaffirming the ability of Evaxion's AI-Immunology platform to precisely select therapeutically relevant vaccine targets. The Phase 2 study is ongoing and continues to generate new valuable insights.

08:29 EDT Metals Company appoints Brendan May to board of directors - TMC the metals company announced the appointment of Brendan May to its Board of Directors as it seeks to harness the potential of deep-seafloor polymetallic nodules for the energy transition and wider global development. As a former Chief Executive of the Marine Stewardship Council and European Chairman of the Rainforest Alliance, Mr. May has spent over two decades at the forefront of sustainability challenges in globally significant ecosystems. In 2010, he formed renowned global sustainability consultancy, Robertsbridge, whose counsel has been sought by leading companies and NGOs around the world.

08:26 EDT KULR Technology announces expiration of SEPA facility, compliance with NYSE - KULR Technology Group will not be extending its Standby Equity Purchase Agreement, with YA II PN, LTD. terminated on June 1, 2024. Furthermore, the Company confirms that it has retired all outstanding debt owed to Yorkville. This marks a significant milestone for KULR as it executes its strategic initiatives, reduces its cash consumption, and otherwise strengthens its financial condition. As previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on April 12, 2024, with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. This announcement is being made solely to comply with the NYSE American LLC Company Guide Section 610(b), which requires public announcement of the receipt of an audit opinion containing a going concern paragraph. This announcement does not represent any change or amendment to the Company's audited financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2023.

08:24 EDT Enphase Energy launches IQ Battery 5P in Canada - Enphase Energy started shipping its most powerful home battery to-date, the IQ Battery 5P, in Canada. The IQ Battery 5P is a modular design with 5 kWh capacity and can be paired with the new IQ8 Microinverters to provide homeowners reliable electricity to use whenever they need it.

08:22 EDT CSW Industrials appoints Darron Ash to board of directors - CSW Industrials announced that its Board of Directors has elected Darron Ash as an independent director. Mr. Ash's addition as a director is part of the Board's succession planning process and comes in anticipation of upcoming age-based director retirements pursuant to the Company's Corporate Governance Guidelines. Currently, Ash serves as the Chief Executive Officer and Executive Board Member for one of the largest privately held companies in the United States, Sammons Enterprises

08:21 EDT Oryzon Genomics announces publication of Phase IIa ALICE results - Oryzon Genomics announced that the final results of the Phase IIa ALICE study evaluating iadademstat in combination with azacitidine in unfit patients with newly diagnosed acute myeloid leukemia were published online in The Lancet Hematology. A summary of the final data from this study had been previously released in an oral presentation at the 2022 American Society for Hematology annual meeting, where it was selected as one of the 25 most relevant communications in AML. This notable publication is a continuation of Oryzon's previous pioneering research featured in the Journal of Clinical Oncology and Cancer Cell, cementing the company's position at the forefront of epigenetics in oncology and LSD1 innovation. The combination of iadademstat with azacitidine induced a high proportion of responses, with 22 of 27 patients in the efficacy analysis set having an objective response. Notably, 52% of patients had either a complete remission or complete remission with incomplete hematological recovery in the ALICE trial. For comparison, the percentage of patients who experienced a CR/CRi in the intention-to-treat azacitidine populations was 28% in the acute myeloid leukaemia-001 trial, 28% in the VIALE A trial, and 27% in the Monarch trial. Most of the responses occurred rapidly and 36% lasted 12 months or longer. At database lock, nine patients were alive and as of February, 2024, five patients remain alive, with three continuing treatment under compassionate use after four years. The CR/CRi responses in ALICE were generally deep, as determined by the high rate of measurable residual disease negativity, which is associated with improved survival. Remarkably, responses were seen across the entire adverse prognostic mutational landscape. Of note are the responses in specific subgroups: Three patients with M5 AML had CR/CRi with iadademstat plus azacitidine, with 100% measurable residual disease negativity. In patients with AML with TP53 mutations in combination with a complex karyotype or high variant allele frequency, or both, CR/CRi was reached in 63%, with a duration of response of 7.9 months and a median overall survival of 10 months. Responses in leukemias harboring other poorer-prognosis mutations were also encouraging. All seven patients harboring a mutation or mutations in the RAS pathway responded, with a median overall survival of 467 days. Patients harboring mutations in DNM3TA, NPM1, and RUNX had 100% response rates, mostly CR or CRi. As a continuation of ALICE, Oryzon is further expanding the clinical development of iadademstat in 1L unfit AML through an Investigator-initiated study led by Oregon Health & Science University. This trial is a Phase Ib dose-finding study to evaluate iadademstat in combination with the SoC, venetoclax and azacitidine, in first-line AML patients and is expected to begin enrolling patients in the coming weeks. Iadademstat is currently being evaluated also in combination with gilteritinib in relapsed/refractory AML patients harboring a FLT3 mutation in the FRIDA study, an open-label, multicenter Phase Ib trial being conducted in the US and which plans to accrue up to approximately 45 patients. The first two cohorts have been completed and the combination was safe and showed strong antileukemic activity. Following the FDA's new OPTIMUS doctrine, the company continues to explore the minimal dose with clinical activity, and a third cohort has been started and is recruiting. Preliminary results from this trial will be presented at the upcoming European Hematology Association (EHA) 2024 congress in June. In addition, in neuroendocrine tumors, in the context of the CRADA agreement between Oryzon and the NIH, the NCI is sponsoring a randomized Phase I/II trial in 1L extensive disease small cell lung cancer combining iadademstat with immune checkpoint inhibitors. The IND for this trial was recently approved by the FDA.

08:19 EDT LL Flooring mails letter to shareholders highlighting 'qualified' directors - LL Flooring Holdings mailed a letter to shareholders in connection with the filing of its definitive proxy statement with the Securities and Exchange Commission SEC for its upcoming 2024 Annual Meeting of Stockholders. The Company also launched www.VoteLLFlooring.com, which provides additional information and resources to help shareholders vote at the 2024 Annual Meeting of Stockholders. The letter contains critical information for shareholders' decision-making, including: LL Flooring has a highly qualified and engaged Board with the right mix of skills and expertise to oversee the Company's strategic direction. The company's Board of Directors and management team have determined a set of five strategic priorities and are taking decisive action to deliver on those priorities to drive value creation. The Board is also taking action to address near-term financing needs. Through its previously announced strategic alternatives review process, the Board has been carefully and thoroughly evaluating and engaging with third parties regarding indications of interest and non-binding proposals to acquire the company. Thomas Sullivan has launched a proxy contest that is self-serving, personal and not in the best interests of all shareholders, and the Board believes he would push a personal agenda to acquire LL Flooring at a price that may undervalue the company if elected to the Board. Jerald Hammann, who has nominated himself to the Board, only owns a few shares of the company's stock, lacks a cogent plan for LL Flooring and is not qualified to serve on LL Flooring's Board.

08:18 EDT Fangdd Network announces termination plan for ADR facility - Fangdd Network Group announced that the Company and The Bank of New York Mellon intend to terminate the Deposit Agreement, dated October 31, 2019, among FangDD, The Bank of New York Mellon, as the depositary for the Company's American depositary shares, and owners and holders of ADSs. As a result, the Company's existing American depositary receipts facility is expected to be terminated at 5:00 p.m. on September 4, 2024. Immediately following the termination of the Company's ADR facility, the Company plans to list its Class A ordinary shares for trading on The Nasdaq Stock Market in substitution for its ADSs.The Company expects that, upon the effectiveness of the Substitution Listing, its ADSs will cease to be listed on Nasdaq while the Class A ordinary shares represented by the ADSs will trade on Nasdaq under the symbol of "DUO." The Company has appointed VStock Transfer, LLC as its transfer agent in the United States for the Substitution Listing. The Bank of New York Mellon will issue a termination notice to owners and holders of ADSs represented by the Company's Class A ordinary shares on June 3, 2024, which will provide more information regarding the ADR facility termination. There remains uncertainty regarding whether the Company will be able to obtain clearance from Nasdaq to effectuate the Substitution Listing prior to the Termination Date. Subsequent to the Termination Date, Nasdaq may suspend the trading of the Company's ADSs until such time as the Substitution Listing shall have taken effect or as otherwise determined by Nasdaq. In connection with the termination of the Company's ADR facility, the Company will hold an extraordinary general meeting of shareholders at Room 4106, Building 12B1, Shenzhen Bay Ecological Technology Park, Nanshan District, Shenzhen, People's Republic of China on July 11, 2024 at 10:00 am Beijing time, for the purposes of considering and, if thought fit, passing the proposed resolutions set forth in the notice of EGM.

08:16 EDT GSK: Jemperli continues to show 'unprecedented results, in dMMR rectal cancer - GSK announced updated, longer-term results from the phase II supported collaborative study with Memorial Sloan Kettering Cancer Center evaluating Jemperli or dostarlimab-gxly as a first-line treatment-as an alternative to surgery-for mismatch repair deficient dMMR locally advanced rectal cancer. The trial showed an unprecedented 100% clinical complete response rate cCR in 42 patients who completed treatment with dostarlimab-gxly, defined as complete pathologic response or no evidence of tumors as assessed by magnetic resonance imaging, endoscopy and digital rectal exam. In the first 24 patients evaluated, a sustained clinical complete response with a median follow-up of 26.3 months was observed. These late-breaking data are being presented today at the 2024 American Society of Clinical Oncology ASCO Annual Meeting in Chicago, IL as a rapid oral presentation . The latest research presented today from the phase II trial builds on the findings initially presented in a late-breaking presentation at the 2022 ASCO Annual Meeting with simultaneous publication in The New England Journal of Medicine.1

08:16 EDT Rigel Pharmaceuticals highlights new data in three poster presentations at ASCO - Rigel Pharmaceuticals announced the presentation of three posters at the 2024 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago, IL today and online. Presentations include five-year results from the pivotal cohort of the registrational Phase 2 trial of REZLIDHIA for the treatment of relapsed or refractory mutated isocitrate dehydrogenase-1 acute myeloid leukemia, the safety and efficacy of olutasidenib treatment in a subgroup analyses of elderly patients with R/R mIDH1 AML, and an overview of the ongoing Phase 1b trial of R2891, a potent and selective inhibitor of IRAK1 and IRAK4, in patients with lower-risk myelodysplastic syndrome. "Our presentations at ASCO build on the strength of REZLIDHIA's data, reinforcing its important role in the R/R mIDH1 AML treatment landscape. REZLIDHIA continues to demonstrate durable responses and was well tolerated, even in difficult to treat and elderly patients with mIDH1 AML who have more safety concerns," said Raul Rodriguez, Rigel's president and CEO. "In addition, we are sharing an overview of the ongoing Phase 1b trial of R289 in lower-risk MDS, an area of high unmet need. We believe R289 could potentially provide a new treatment option to patients who have failed other agents."

08:15 EDT Scorpius Holdings, Beyond Imagination enter partnership for humanoid robots - Scorpius Holdings announced a strategic partnership with Beyond Imagination, a US-based developer of autonomous AI-powered humanoid robots. The goal of the collaboration is to introduce advanced AI robotics to enhance biomanufacturing productivity and efficiency, as well as bolster US preparedness for pandemics and other crises. The partnership aims to address the significant challenges posed by the increased demand for rapid-scale biomanufacturing and the limited supply of skilled labor. At the heart of this effort is the introduction of Beyond's autonomous humanoids that possess the ability to learn from and collaborate with human colleagues, continuously improving their capabilities. AI robotics have been deployed in other industries, where they excel at learning new procedures and protocols and deploy these learnings to exacting standards. Beyond's AI robotics platform has the potential to seamlessly integrate into existing workflows in the biomanufacturing regulated environment, thereby enhancing both efficiency and output.

08:14 EDT Post Holdings announces leadership changes at Weetabix, Refigerated Retail - Post Holdings announced planned executive leadership changes at its Weetabix and Refrigerated Retail businesses. These transitions and internal promotions are part of the company's ongoing business succession planning. Sally Abbott, Managing Director, will transition to a strategic advisor role effective Oct. 1, 2024, through her planned retirement on March 31, 2025. Colm O'Dwyer, currently Commercial Director for Weetabix, will succeed Abbott as Managing Director, effective Oct. 1, 2024. Abbott joined Weetabix in 2008 as Marketing Director, prior to Post's ownership which began in 2017. O'Dwyer joined Weetabix in 2016 from Coca-Cola Enterprises in the U.K., eventually becoming General Manager of the Weetabix On-The-Go business. Abbott and O'Dwyer will continue working closely together through March of next year to ensure a smooth business transition. Weetabix is currently evaluating candidates to backfill the Commercial Director role vacated by O'Dwyer's promotion. Mark Delahanty, President and Chief Executive Officer of Post Refrigerated Retail, will transition to a strategic advisor role on Dec. 1, 2024, through his planned retirement date of May 31, 2025. Mike McCoy, currently Executive Vice President and CFO of Post Refrigerated Retail, will succeed Delahanty as President and CEO, effective Oct. 1, 2024. Delahanty and McCoy will continue working closely together through May 2025 to ensure an orderly transition of the business. Adam Gonsiorowski, with Bob Evans Farms since 2014 and in his current role as Vice President of Finance since 2019, will assume the role of Chief Financial Officer on Oct. 1, 2024, reporting to McCoy.

08:13 EDT 23andMe announces preliminary Phase 2 safety results for 23ME-00610 at ASCO - 23andMe Holding Co. announced positive preliminary Phase 2 safety and efficacy data from 23ME-00610, a first-in-class anti-CD200R1 antibody, presented at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago, May 31-June 4. 23andMe presented two posters on 23ME-00610, one each from neuroendocrine and ovarian cancer patient cohorts in its ongoing Phase 1/2a clinical trial. Key takeaways: Confirmed partial response in patient with well-differentiated pancreatic neuroendocrine cancer and qualitative clinical benefit with durable treatment duration and tumor shrinkage in patient with mesonephric adenocarcinoma. 23ME-00610 monotherapy demonstrates acceptable safety and tolerability, and achieves the prespecified targets for maximal pharmacology at 1400 mg dosed every three weeks. From archival tumor immunohistochemistry analyses, over 70% of patients had detectable tumor cell CD200, and higher expression tended to trend with clinical benefit. In addition to CD200, histology data suggest that immunosuppressed tumors may be more likely to exhibit disease control with 23ME-00610. "We continue to be pleased with the progress of 23ME-00610 as monotherapy, which continues to demonstrate therapeutic potential for inhibiting CD200R1 in cancer patients," said Jennifer Low, M.D., Ph.D, Head of Therapeutics Development. "We are also seeing evidence of CD200 emerging as a potential biomarker associated with 23ME-00610 monotherapy efficacy. Further, we are encouraged by the continued safety and tolerability profile of 23ME-00610 which, as presented at AACR earlier this year, points to potential combination strategies for added therapeutic benefit in cancer patients."

08:13 EDT Replimune Group presents positive data from RP1 and RP2 programs at ASCO - Replimune Group presented two oral presentations highlighting promising clinical data from its RP1 and RP2 programs at the 2024 American Society of Clinical Oncology, ASCO, Annual Meeting taking place May 31-June 4 in Chicago. The data continues to show that the combination of RP1 and nivolumab in anti-PD-1 failed melanoma provides deep and durable responses with an "on-target" safety profile with generally transient grade 1/2 adverse events, indicative of systemic immune activation. Approximately one third of patients experienced a response, with an overall response rate by investigator assessment of 32.7%. In the 94 patients who had primary resistance to their immediate prior anti-PD-1 therapy, the ORR was 34%. In the 66 patients who progressed on prior anti-PD-1 combined with anti-CTLA-4 therapy, the ORR was 27.3%. All responses lasted greater than six months from enrollment, with a median duration of response exceeding 36 months. "The strength of the RP1 and RP2 data being presented at ASCO in two hard-to-treat tumor types further validates the potential of the RPx platform," said Sushil Patel, CEO of Replimune. "In the IGNYTE trial, the investigator-assessed 12-month results show an overall response rate of 32.7% that was highly durable, and the combination provided a favorable safety profile, all consistent with previous data. The data with RP2 as monotherapy and in combination with nivolumab in refractory patients highlights a strong and durable overall response rate of nearly 30 percent in uveal melanoma where treatment options are limited."

08:11 EDT FOREWARN partners with Vermont Association of REALTORS - FOREWARN announced that Vermont Association of REALTORS will offer FOREWARN services to its 1,800+ members it serves throughout the State of Vermont to promote proactive real estate agent safety.

08:10 EDT Valens Semiconductor acquires Acroname - Valens Semiconductor announced the acquisition of Acroname, a pioneering company specializing in advanced automation and control technologies. The acquisition enables Valens to expand its position in the industrial market with a holistic USB-focused offering that includes Valens' innovative USB extension chipsets, augmented by Acroname's unique technology and expertise. "We are excited to welcome Acroname to the Valens team," said Gideon Ben Zvi, CEO of Valens Semiconductor. "By incorporating Acroname's technology and expertise into our USB offering, we will be able to deliver a unique value proposition to the industrial market, enabling the long-distance extension and seamless switching of Hi-Speed and SuperSpeed USB devices. This acquisition, our first M&A transaction, is an important milestone in our strategy of expanding our offering to multiple industries and increasing our value add for our customers."

08:09 EDT TransAct Technologies actively assessing strategic alternatives, including sale - TransAct Technologies announced an update to its previously announced strategic business review. The company is actively assessing strategic alternatives with the assistance of Roth Capital Partners the Company's advisor. The Company has engaged in preliminary discussions with potential strategic partners. Additionally, the Board of Directors has formed an independent committee to consider the full range of strategic, operational, and financial alternatives to maximize stockholder value, which may include a potential sale of part of or the entire business of the Company and the development and implementation of new strategies designed to grow the Company's business. "TransAct's casino business remains a market leader with growth prospects existing globally. As inventories in the industry normalize, we fully expect the business to continue to produce stable and growing returns," said John Dillon, Chief Executive Officer of TransAct. "The FST business, despite the loss of 7-Eleven's label business, is growing. We have added a number of new customers with significant growth opportunities and, in addition, a large global QSR client has successfully procured more than 1,000 units of our new BOHA! Terminal 2 since the beginning of this year." "While we focus externally on strategic initiatives, we will continue to prioritize internal initiatives that improve and refine operational execution within each functional area of the business," continued Mr. Dillon.

08:08 EDT Aethlon Medical provides update on planned Phase 1 trial of Hemopurifier - Aethlon Medical provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda or Opdivo. "We continue to make progress preparing for our planned, safety, feasibility and "dose finding" oncology trials in Australia and India, and want to provide our shareholders and other constituents with an update," stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical. "In early May, we announced new data showing the in vitro removal of exosomes from cancer patient plasma using a miniature version of our Hemopurifier. This data has been quickly integrated into the required documentation for Ethics Committees at our potential clinical sites. On May 17, 2024, we provided these documents to the Contract Research Organizations for these planned clinical trials. Subsequently, on May 24, 2024, one potential site submitted the documents to its Ethics Board. An additional site in Australia and another in India are currently assembling the packages for submission to their Ethics Committees."

08:07 EDT Mercantile Bank implements management succession plan - Mercantile Bank implemented the following resignations and appointments, in furtherance of its previously announced management succession plan, effective as of June 1, 2024: Robert Kaminski, Jr. has retired as President and Chief Executive Officer of Mercantile and as CEO of Mercantile's wholly owned subsidiary, Mercantile Bank. Kaminski remains a Director of both Mercantile and the Bank. Raymond Reitsma has resigned as Executive Vice President and Chief Operating Officer of Mercantile and has been appointed as President and CEO of Mercantile and CEO of the Bank. Scott Setlock has been appointed as EVP, COO, and Secretary of Mercantile and as Secretary of the Bank. Setlock remains EVP and COO of the Bank. Mr. Setlock was appointed to the role of EVP, COO, and Secretary of Mercantile effective January 1, 2024, and has served as EVP and COO of the Bank since January 1, 2022.

08:05 EDT Omega Healthcare provides update on LaVie Care Centers restructuring - Omega Healthcare issued the following statement in response to LaVie Care Centers' announcement that it had filed for Chapter 11 bankruptcy protection in the Northern District of Georgia. "Omega believes this filing is a necessary and important step in creating an entity that is operationally solvent and sustainable, with enhanced liquidity and a strengthened balance sheet. During this filing, our focus, like LaVie's, is on maintaining quality of care for the residents of these facilities, on supporting the employees that devote their careers to delivering this care, and on the key vendors that help provide operational services. As such, we have elected to commit $10 million to fund 50% of the expected debtor-in-possession financing, in order to support sufficient liquidity to effectively operate the facilities during bankruptcy. We continue to believe that there is meaningful value in our portfolio of LaVie assets. Omega has been working with LaVie for over a year to reduce its exposure to underperforming assets, and we believe this has meaningfully enhanced the operating performance of our LaVie portfolio. We believe the current cash flow generated by our remaining LaVie portfolio is sustainable and will support long-term annualized rent of $36 million, while also retaining sufficient cash within the business to provide for strong clinical care. As part of our debtor-in-possession loan commitment, during the period of bankruptcy protection, LaVie is required to pay Omega monthly rent of $3 million related to the 30 properties LaVie continues to lease from Omega, all subject to court approval. The proposed DIP budget, which provides for LaVie rent, anticipates confirmation of the plan or sale of assets by the end of this year. However, this projection, along with all elements of the bankruptcy filing process, is subject to the approval of the bankruptcy court and other complexities inherent in Chapter 11 proceedings."

08:04 EDT US Signal to acquire OneNeck from TDS - US Signal Company has entered into a definitive agreement to acquire OneNeck IT Solutions and OneNeck Data Center Holdings from Telephone and Data Systems, a provider of wireless, broadband, video, voice, hosted and managed services to U.S. businesses. The firms expect the transaction to close in the third quarter of 2024 subject to customary closing conditions. No terms were disclosed. The acquisition will: Increase the number of US Signal data centers from nine to 15, quadrupling square footage; Extend US Signal's footprint to the West Coast with the addition of Phoenix, Arizona; Denver, Colorado; and Bend, Oregon data centers; Add OneNeck's Madison, Wisconsin; Minneapolis, Minnesota; and Des Moines, Iowa markets to US Signal's fiber network; More than triple commercial power under management

08:03 EDT Live Oak Bancshares enters embedded banking partnership with Anatomy Financial - Live Oak Bank has announced its first embedded banking partnership with Anatomy Financial Inc., an AI-powered financial automation solution for medical, dental, digital health, and healthcare billing companies. Live Oak's novel approach is the first of its kind, enabling software companies such as Anatomy to directly deliver Live Oak banking products and services to customers. The result is a collaboration where customers will receive best-in-class banking services conveniently embedded in the software they use the most. While these accounts are held at and serviced by Live Oak Bank, the product is exclusively available for customers on the Anatomy platform.

08:02 EDT MicroStrategy to pay $40M to District of Columbia to settle civil complaint - In a regulatory filing, MicroStrategy stated: "As previously reported, on August 31, 2022, the District of Columbia, through its Office of the Attorney General, filed a civil complaint in the Superior Court of the District of Columbia naming as defendants (i) Michael J. Saylor, the Chairman of the Board of Directors of MicroStrategy Incorporated and the company's Executive Chairman, in his personal capacity, and (ii) the company. The District sought, among other relief, monetary damages under the District's False Claims Act for the alleged failure of Mr. Saylor to pay personal income taxes to the District over a number of years together with penalties, interest, and treble damages. The complaint also alleged in the sole claim against the company that it violated the District's False Claims Act by conspiring to assist Mr. Saylor's alleged failure to pay personal income taxes. On February 28, 2023, following a motion to dismiss filed by Mr. Saylor and the company, the court dismissed the sole claim against the company and the claim against Mr. Saylor alleging violation of the District's False Claims Act. On May 10, 2023, the court granted the District's motion to amend its complaint to restore claims under the False Claims Act against both Mr. Saylor and the company. The amended complaint alleged that the company violated the District's False Claims Act by making and using false records and statements in the form of false withholding filings with the District Office of Tax and Revenue. The amended complaint also alleged that Mr. Saylor violated the District's False Claims Act by making and using false records and statements and by causing the company to make and use false records and statements. On May 31, 2024, the District, Mr. Saylor, and the company stipulated to the entry of a Consent Order and Judgment with the court pursuant to which the District, upon receipt of all amounts due under the Consent Order, released Mr. Saylor and the company from all claims and liabilities that the District asserted, could have asserted, or may assert in the future based on the conduct described in the complaints filed in the case. Under the Consent Order, which is subject to entry by the court, Mr. Saylor and the company do not admit to any of the allegations encompassed by the conduct described in the complaint, any violation of law or regulation, any other matter of fact or law, or any liability or wrongdoing, and agree to pay $40,000,000 to the District to settle the case and resolve the litigation with the District. Pursuant to a separate agreement between Mr. Saylor and the company, and following the court's entry of the Consent Order, Mr. Saylor will pay this settlement amount to the District in full and the company will not be obligated to make any contribution to the settlement payment." Reference Link

08:01 EDT Landsea Homes closes on 44 homesites for a new community in California - Landsea Homes announced it has closed on 44 homesites for a new community called Mason in Anaheim, California. Land development has already begun, and sales are anticipated to start later this year. "We are excited to grow our presence in Orange County with the addition of Mason to our new home community portfolio," said Tom Baine, California Division President, Landsea Homes. "Nolin, another Anaheim community of ours across the street from Mason, sold out less than two years after opening for sale and experienced unprecedented demand. We anticipate interest for Mason to be just as strong and look forward to meeting the demands of local homebuyers with these new high-quality, High Performance Homes."

07:54 EDT Welltower increases quarterly dividend 10% to 67c per share - Welltower announced that it expects to increase its quarterly common stock dividend to $0.67 per share, beginning with the second quarter of 2024. The declaration and payment of any future dividend remains subject to further review and approval by the Board.

07:46 EDT FTAI Aviation commences cash tender offer for senior notes - FTAI Aviation is announcing that Fortress Transportation and Infrastructure Investors has commenced an offer to purchase for cash up to $100,000,000 aggregate principal amount of its outstanding 9.750% Senior Notes due 2027 on the terms and conditions described in FTAI LLC's Offer to Purchase, dated June 3, 2024. Capitalized terms used but not defined in this announcement have the meanings given to them in the Offer to Purchase. The Tender Offer will expire at 5:00 p.m., New York City time, on July 2, 2024 unless extended or earlier terminated by FTAI LLC. FTAI LLC reserves the right to amend, extend or terminate the Tender Offer at any time subject to applicable law.

07:43 EDT Bitfarms earns 156 bitcoin in May - Bitfarms provides its monthly production report and update on its fleet upgrade and expansion. In May, Bitfarms secured an additional 100 MW at its Yguazu site through an amendment to the existing 100 MW Power Purchase Agreement with the Paraguay state-owned utility, ANDE. This amendment doubles capacity at this site to 200 MW with scheduled deployment for the additional 100 MW in 2025. This sustainable hydropower will be provided at the same contractual low cost of approximately 3.9 cents per kWh, before VAT, with the added benefit of not being subject to annual inflationary adjustments. This expansion has the potential to add an additional 6 EHs in 2025 if filled with S21 Pro miners. "Our fleet upgrade is progressing at a rapid pace. Year-to-date we have received 25,600 miners and installed 23,600 miners, with the remaining 16,200 miners in route. Together, these miners provide sufficient hashing power to achieve 12 EH/s in June," said Ben Gagnon, Chief Mining Officer. "In May, we completed two farm upgrades at Cowansville and Bunker and filled three of five buildings in Paso Pe with new miners. This increased our installed hashrate to 9.5 EH/s, with approximately 7.5 EH/s currently operating, and improved our corporate energy efficiency by 31% year-over-year and 13% from last month, to 27 w/TH. Nearly 2 of 3 EH/s are installed at our Paso Pe site but not yet energized pending final testing by ANDE and substation engineering work which is scheduled to be completed in June. Upgrades at Leger are underway and are scheduled to be completed in June along with farm upgrades at St Hyacinthe and Baie Comeau."

07:39 EDT Venus Concept announces approval for Venus Versa Pro in Canada - Venus Concept has received a medical device license issued by Health Canada to market the Venus Versa Pro system in Canada. The Venus Versa Pro is a comprehensive aesthetic platform which houses the latest technologies in one device to offer a total skin rejuvenation experience. The synergizing of Intense Pulsed Light with SmartPulse, NanoFractional Radio Frequency with SmartScan, and Venus Concept's proprietary (MP) technology enable clinicians to provide a range of procedures to enhance skin tone, improve tightness and smooth texture.

07:37 EDT Neurocrine announces CAHtalyst Pediatric Phase 3 study met primary endpoint - Neurocrine Biosciences announced that the primary study results from its CAHtalyst Pediatric Phase 3 study investigating crinecerfont for the treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency have been published in The New England Journal of Medicine online edition and will appear in a future print issue of the journal. The CAHtalyst Pediatric Phase 3 study met the primary and key secondary endpoints related to androgen reduction and glucocorticoid dose reduction while maintaining androgen control. Favorable trends were observed with endpoints that reflect the consequences of long-term supraphysiologic glucocorticoid therapy and androgen excess. In addition to appearing in The New England Journal of Medicine, CAHtalyst Pediatric Phase 3 data were presented at ENDO 2024. The Phase 3 Pediatric study met the primary endpoint of change from baseline in androstenedione following the initial 4-week GC-stable period. Crinecerfont treatment led to a significantly greater reduction in androstenedione compared to an increase with placebo at Week 4 .

07:35 EDT FDA accepts Neurogene's NGN-401 gene therapy for Rett into START Pilot program - Neurogene announced that its NGN-401 gene therapy for Rett syndrome has been selected to participate in the U.S. Food and Drug Administration FDA Support for Clinical Trials Advancing Rare Disease Therapeutics START Pilot Program. As part of the START Program, Neurogene will have opportunities for enhanced communications with the FDA, with the aim to further accelerate the pace of NGN-401's development. These opportunities are designed to provide frequent advice and regular ad-hoc conversations to address product-specific development issues, including, but not limited to, clinical study design, choice of control group and fine-tuning the choice of patient population. "We are honored that NGN-401 gene therapy for Rett syndrome has been chosen as one of only three CBER programs for FDA's START Pilot Program and are grateful that the FDA has committed to investing significant Agency resources to accelerate development of NGN-401," said Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene

07:34 EDT Biogen, Delta Flight Products collaborate for accessible air travel - Biogen Inc. (BIIB) and Delta Flight Products (DAL) announced that the companies will collaborate to inform future enhancements to the air travel journey for passengers with reduced mobility. In the United States alone, approximately 5.5 million individuals rely on wheelchairs for mobility. The companies will connect with individuals living with rare disease mobility restrictions at community events to listen and learn about their travel experiences and specific needs. Through these interactions, Biogen and DFP aim to better understand the experiences of passengers with reduced mobility, identify gaps and unmet needs in travel accessibility, and inform future innovations and tools aimed at creating a more equitable flying experience.

07:33 EDT Arrowhead announces topline results from PALISADE study - Arrowhead announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome, or FCS, a severe genetic disease with significant unmet need and no FDA approved therapies. PALISADE successfully met the primary endpoint of lowering triglycerides and met all key secondary endpoints, including reducing the incidence of acute pancreatitis compared to placebo. The primary endpoint for the PALISADE study was placebo adjusted median change in triglycerides at Month 10. At that timepoint, patients treated with quarterly doses of 25 and 50 mg plozasiran achieved median triglyceride reductions of 80% and 78%, respectively, with a maximal reduction of 98%. At month 12, patients treated with 25 and 50 mg plozasiran achieved median triglyceride reductions of 78% and 73%, respectively, with a maximal reduction of 99%. These compared with median triglyceride reductions in placebo-treated patients of 17% at month 10 and -7% at month 12. Mean reductions in Apolipoprotein C-III at month 10 were 88% and 94% at 25 and 50 mg plozasiran, respectively. In addition to meeting the primary endpoint, plozasiran met all key secondary endpoints and demonstrated statistical significance versus placebo. There were 4 multiplicity-controlled key secondary endpoints: 1) percent change from baseline at Months 10 and 12 (averaged) in fasting triglycerides; 2) percent change from baseline at Month 10 in fasting APOC3; 3) percent change from baseline at Month 12 in fasting APOC3; 4) incidence of positively adjudicated events of acute pancreatitis during the randomized period. Plozasiran demonstrated a favorable safety profile in the PALISADE study. The number of subjects reporting treatment emergent adverse events, or AEs, were similar in plozasiran and placebo groups. Severe and serious AEs were less common with plozasiran than with placebo. The most common AEs reported were abdominal pain, COVID-19, nasopharyngitis, headache and nausea. Arrowhead plans to highlight recent data for its cardiometabolic pipeline at its June 25, 2024, Cardiometabolic event as part of the 2024 Summer Series of R&D Webinars. The company also plans to present full results from the Phase 3 PALISADE study at upcoming medical congresses and will begin to engage with global regulatory authorities about these data.

07:32 EDT Prairie Operating Co. set to join Russell 3000 Index - Prairie Operating Co. is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to the list of additions posted Friday, May 31st.

07:31 EDT Abeona Therapeutics announces employee inducement grants - Abeona Therapeutics has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On May 31, 2024, the Compensation Committee of Abeona's Board of Directors granted restricted stock equity awards as a material inducement to employment to three individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 5,500 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee's continued employment with Abeona on the applicable vesting dates.

07:26 EDT Enthusiast Gaming's Luminosity hosts 'Get On My Level' event - Enthusiast Gaming Holdings announced that its 10th anniversary edition of the Get On My Level event, hosted by Luminosity in partnership with Even Matchup Gaming, reached over 200,000 unique online viewers and peaked at over 60,000 concurrent online viewers while hosting a standing-room-only in-person crowd. The event was held at the Sheraton Centre Toronto Hotel where over 2,500 live attendees participated in three days of live entertainment and high stakes competition, featuring a variety of fighting game titles, headlined by Super Smash Bros Melee and Super Smash Bros Ultimate, and including Rivals 2, Guilty Gear: Strive, Nickelodeon All-Star Brawl 2, Street Fighter 6, and Tekken 8. Event sponsors included Domino's Pizza, Kids Help Phone, Focus Fuel, and Experience Ontario. The event garnered tremendous engagement across its audience, with the primary Twitch stream broadcast reaching over 10.8% chat engagement and the average viewer consuming over 104 minutes of content, longer than many feature-length films. The chat engagement qualifies Get On My Level X as one of the most engaged esports event chats in 2024.

07:25 EDT Whitestone REIT appoints Amy Feng as chair of Board of Trustees - Whitestone REIT announced that the Board of Trustees has appointed Amy Feng, an independent Trustee, as the Chair of Whitestone's Board of Trustees, and Julia Buthman, also an independent Trustee, as Chair of the Board's Nominating and Governance Committee. Mss. Feng and Buthman joined the Board in July of 2022 and May of 2023 respectively, and both have played a vital role in overseeing management's successful turnaround strategy. The Company is in the process of engaging a well-known national search firm to conduct a comprehensive search to identify two new independent board members to replace current trustees, David Taylor and Nandita Berry. Mr. Taylor and Ms. Berry plan to step down from their roles once their highly qualified successors are appointed or elected to the Board.

07:22 EDT Osisko Development to compldte second deferred payment installment - Osisko Development announces that, in accordance with the terms of the Company's previously-completed acquisition of a 100% ownership interest in the Tintic Project, located in Utah, U.S.A., in May 2022, the Company intends to satisfy the second of five deferred payments to the sellers of the Tintic Project in common shares of the Company. The Second Deferred Payment of $2,500,000 is expected to be paid entirely in Common Shares at a deemed price of C$2.7829 per Common Share, resulting in the issuance of 1,228,394 Common Shares to the Sellers in full satisfaction of the Second Deferred Payment. The issuance of the Common Shares in satisfaction of the Second Deferred Payment remains subject to the approval of the TSX Venture Exchange.

07:20 EDT ETFS Capital responds to ISS campaign for WisdomTree board change - The company stated: "ETFS Capital Limited, the largest combined owner of common stock, $0.01 par value, and Series A Non-Voting Convertible Preferred Stock of WisdomTree, with ownership of approximately 10% of the outstanding Common Stock, which together with its Series A Preferred Stock would represent approximately 18% of the Company's outstanding Common Stock on an as-converted basis, responded to reports from Institutional Shareholder Services Inc., and Glass, Lewis & Co, on its campaign for stockholders to vote Against the re-election of the Chairman Win Neuger, Director Anthony Bossone, and CEO and Director Jonathan Steinberg, to the board of directors of WisdomTree as a referendum against long-tenured directors and to demonstrate stockholder support for a truly independent process to maximize stockholder value." Graham Tuckwell, ETFS Capital Chairman commented: "ISS and Glass Lewis recognize that ETFS Capital has been a driving force for major improvements in WisdomTree's governance. As the largest stockholder of the Company, we are directly aligned with other stockholders and are acting in our collective best interests. We believe the proxy advisors, however, put too much faith in the management team's abilities to develop the DeFi business, particularly in the face of what appears to be a spectacular failure to capitalize on the surge of interest in Bitcoin ETFs. As ISS acknowledged, the Company has a poor track record of providing investors with the information they need to evaluate the Board's approach to capital allocation and the success or failure of key business initiatives. We believe stockholders simply cannot afford another year of lost opportunities and value destruction under this Board and management team. We deliberately chose not to nominate directors for the 2024 Annual Meeting. Despite our success in driving important governance changes, we believe stockholders have not benefitted from those changes due to the Board's continued intransigence and failure to provide investors with any meaningful information about the DeFi business. We call on our fellow stockholders to join us in sending an unequivocal message to the long-tenured directors and the Board, who refuse to take the steps necessary to unlock value for all stockholders."

07:18 EDT Quince Therapeutics announces fast track designation for EryDex System - Quince Therapeutics announced that the FDA has granted Fast Track designation for its EryDex System for the treatment of patients with Ataxia-Telangiectasia, or A-T. EryDex is comprised of dexamethasone sodium phosphate, or DSP, encapsulated in a patient's own red blood cells utilizing Quince's proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform. DSP is a corticosteroid well known for its anti-inflammatory properties as well as its dose-limiting toxicity due to adrenal suppression. EryDex is designed to provide the efficacy of corticosteroids and to reduce or eliminate the significant adverse effects that accompany chronic corticosteroid treatment.

07:16 EDT Dominion announces closing of sale of Questar, Wexpro for $4.3B - Dominion Energy (D) announced closure of the sale of its Salt Lake City, Utah-based natural gas utility Questar Gas Company, and its cost-of-service gas supply company, Wexpro Company, to Enbridge Inc. (ENB) for approximately $4.3 billion, including assumed indebtedness and adjusted for customary closing items. This transaction was previously announced on Sept. 5, 2023.

07:14 EDT Illumina appoints Cunningham as Chief Commercial Officer - Illumina (ILMN) announced the appointment of Everett Cunningham as Chief Commercial Officer, CCO, effective June 10. Cunningham will be responsible for building, guiding, and managing the company's global commercial organization. Most recently, Cunningham served as Chief Commercial Officer at Exact Sciences (EXAS)

07:12 EDT iBio closes sale of manufacturing facility in Texas - iBio announced the closing of the sale of its manufacturing facility located in Bryan, Texas to the Board of Regents of the Texas A&M University System for $8.5 million. Following the issuance of pre-funded warrants having a value of $4.5 million to the lender, Woodforest National Bank, iBio and its wholly owned subsidiary, iBio CDMO LLC, has met all of the conditions of the settlement agreement releasing the Company and its subsidiary of all obligations with respect to the debt secured by the Property. The transaction, coupled with the use of approximately $915K in restricted cash previously held by Woodforest, eliminates approximately $13.2 million in secured debt from iBio's balance sheet.

07:11 EDT RedHill announces new Chinese patent notice of allowance for opaganib - RedHill Biopharma announced the issue of a new Chinese patent notice of allowance for opaganib in combination with immune checkpoint inhibitors as a method of inducing an anti-cancer immune response, providing protection for opaganib's potential use with a range of approved and in-development immune checkpoint inhibitors across a growing range of indications through 2040. The patent will be issued by the Chinese National Intellectual Property Administration, CNIPA. Guy Goldberg, RedHill's Chief Business Officer, said, "This exciting new patent is based on compelling data from a range of in vivo experiments showing significant improvements in outcomes in combination with selected ICIs. China has been a world leader in embracing ICI-based therapy and this is an important addition to the strong patent portfolio protecting opaganib."

07:10 EDT WM to acquire Stericycle for $62.00 per share in cash - Waste Management (WM) and Stericycle (SRCL) announced that they have entered into a definitive agreement under which WM will acquire all outstanding shares of Stericycle for $62.00 per share in cash, representing a total enterprise value of approximately $7.2B when including approximately $1.4B of Stericycle's net debt. The per share price represents a premium of 24% to Stericycle's 60-day volume weighted average price as of May 23, which was the last trading day before an article reported that Stericycle was considering a potential sale. WM expects the transaction to generate more than $125M in annual run-rate synergies. The Stericycle acquisition is expected to be accretive to WM's earnings and cash flows within one year of close. WM currently expects to achieve targeted leverage and return to normal run-rate share repurchases within 18 months of the acquisition's close. The transaction is not subject to a financing condition. WM intends to finance the transaction using a combination of bank debt and senior notes. In the near term, following completion of the transaction, WM expects a net debt-to-EBITDA ratio of approximately 3.4x. The company has a long-standing commitment to a strong balance sheet and solid investment grade credit profile and expects its prudent approach to capital allocation, including a temporary suspension of share repurchases, to position it to achieve a leverage ratio within its targeted net debt-to-EBITDA range of 2.75x to 3.0x approximately 18 months after closing the transaction. The transaction, which was unanimously approved by the boards of directors of both companies, is expected to close as early as the fourth quarter of 2024, subject to the satisfaction of customary closing conditions, including regulatory approvals and approval by a majority of the holders of Stericycle's outstanding common shares.

07:10 EDT Rockwell Automation collaborates with Nvidia to advance intelligent automation - Rockwell Automation (ROK) announces further collaborations with NVIDIA (NVDA) to supercharge the development of safer and smarter industrial AI mobile robots. "We're invigorated by this continued collaboration with NVIDIA," said Ryan Gariepy, CTO, OTTO Motors by Rockwell Automation. "Rockwell's industrial AI expertise, combined with NVIDIA AI and robotics technologies, is going to help drive an exciting new generation of autonomous mobile robots." ..According to the recently released "State of Smart Manufacturing Report," AI ranks as the top feature manufacturers believe will drive the biggest business outcomes. In fact, 83 percent of manufacturers expect to use generative AI in their operations in 2024. As part of this collaboration, the Rockwell Automation PartnerNetwork(TM) now includes NVIDIA, giving Rockwell customers more applications to help make their operations more resilient, agile, and sustainable.

07:08 EDT uniQure receives RMAT designation of AMT-130 in Huntington's Disease - uniQure announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation for its investigational gene therapy AMT-130 for the treatment of Huntington's disease. The FDA granted RMAT designation based on the potential of AMT-130 to address the major unmet medical need among patients with Huntington's disease. The designation follows the FDA's review of interim Phase I/II clinical data for AMT-130 announced in December 2023 and is based on an analysis comparing these 24-month clinical data to a non-concurrent criteria-matched natural history cohort. uniQure expects to provide updated interim data from the ongoing Phase I/II U.S. and European studies of AMT-130 in the middle of 2024. The interim update will include up to three years of follow-up on 29 treated patients, 21 of which will have been followed for at least two years.

07:07 EDT Labcorp announces new strategic service offerings - Labcorp announced new strategic service offerings within its precision oncology portfolio. The enhancements strengthen Labcorp's leadership as a premier, single-source partner for biopharmaceutical companies in advancing cancer research and patient care both in the United States and globally. "Labcorp's portfolio expansion enhances our integrated service offerings and empowers our partners with the support and solutions they need to advance their therapeutic development programs," said Shakti Ramkissoon, M.D., Ph.D., MBA, vice president, medical lead for oncology at Labcorp. "Combined, this can make a lasting difference in patients' lives and health outcomes."

07:07 EDT Carrier completes Global Access Solutions sale, to resume share repurchases - Carrier Global Corporation (CARR) announced it has completed the sale of its security business, Global Access Solutions, to Honeywell (HON) for an enterprise value of $4.95B. Carrier intends to use net proceeds from the sales to pay down debt, expecting to return to ~2x net leverage by the end of 2024. The company also expects to resume share repurchases in 2024. "Today marks the first completed sale as part of Carrier's portfolio transformation," said Carrier Chairman & CEO David Gitlin. "Earlier this year we closed on our Viessmann Climate Solutions acquisition, which will be transformational for Carrier and the industry. We have agreements in place to sell the global Commercial Refrigeration and Industrial Fire businesses, both of which we plan to close in the third quarter. We have also initiated the sale process of our Commercial and Residential Fire businesses. Through these transactions, Carrier will transform into a more focused, higher-growth company ready to address important climate challenges. I want to personally thank the many talented Global Access Solutions employees for their contributions to the business and our customers over the years, and I look forward to watching this business continue to thrive under new ownership."

07:05 EDT Yellow Wood's Suave completes acquisition of ChapStick from Haleon - Yellow Wood Partners announces that its portfolio company, Suave Brands Company, has successfully completed the acquisition of the ChapStick brand from Haleon. This transaction also results in Haleon becoming a shareholder in Suave Brands Company.

07:03 EDT Liquidia says court denies motion for preliminary injunction filed by United Therapeutics - Liquidia (LQDA) announced that on May 31, Judge Andrews of the U.S. District Court for the District of Delaware denied the motion for preliminary injunction filed by United Therapeutics (UTHR) that sought to block the launch of Liquidia's YUTREPIA inhalation powder to treat pulmonary hypertension associated with interstitial lung disease. The ruling reinforces the clear path for the U.S. Food and Drug Administration to issue a final decision on the amended New Drug Application for YUTREPIA. The motion for preliminary injunction was filed in the lawsuit filed by UTHR in September 2023 in which it has alleged YUTREPIA would infringe U.S. Patent No. 11,826,327. While this ruling maintains the status quo in which there is no legal impediment to the FDA granting final approval to YUTREPIA, this lawsuit will continue forward to trial, which is currently scheduled for June 2025. Friday's ruling follows earlier legal rulings from multiple bodies finding that YUTREPIA does not infringe any valid claim of the patents previously asserted by UTHR, including the decision by the Patent Trial and Appeal Board, affirmed by the U.S. Court of Appeals for the Federal Circuit, that all claims of U.S. Patent No. 10,716,793 to be unpatentable. UTHR has stated that it plans to appeal the Federal Circuit's affirmation of the invalidity of the '793 Patent to the United States Supreme Court. Separately, UTHR has also appealed Judge Andrews' ruling to set aside an injunction that he had previously issued blocking the launch of YUTREPIA based solely on the '793 Patent.

07:00 EDT Alpine Income announces sale of senior portion of first mortgage loan investment - Alpine Income Property Trust has sold a $13.6 million A-1 participation interest in its $23.4 million loan investment. The Portfolio Loan is secured by a first mortgage on a portfolio that currently consists of 39 retail properties. As part of the transaction, the Company had the Portfolio Loan rated by an independent rating agency whereby it received an A- rating. PINE originated the Portfolio Loan in November 2023 as a $24.0 million loan at a rate of 8.75%, with the Loan Collateral consisting of 41 retail properties. As of June 3, 2024, two properties within the portfolio have been sold, resulting in principal paydowns that have reduced the overall loan balance to approximately $23.4 million. After adjusting for the Loan Participation Sale, PINE's remaining investment in the Portfolio Loan is approximately $9.8 million at an interest rate of approximately 9.94%. The senior participation of $13.6 million will be repaid on a priority basis with proceeds from any sale of Loan Collateral properties.

06:58 EDT Aecom awarded U.S. nationwide program management services contract by FEMA - AECOM announced that the U.S. Department of Homeland Security's Federal Emergency Management Agency has awarded AECOM a single-award professional services contract that has a one year base period with two one-year option periods that can be exercised at the government's discretion to provide advisory and program management services to its four Consolidated Resource Centers in Winchester, VA; Denton, TX; Sacramento, CA and Guaynabo, Puerto Rico. Under the contract, AECOM will support FEMA's Public Assistance grant program which is focused on repairing and/or replacing damaged public infrastructure after catastrophic disasters.

06:54 EDT Lindsay announces irrigation project valued at over $100M - Lindsay Corporation has entered into a multi-year supply agreement to provide Zimmatic irrigation systems and the Company's FieldNET remote management and scheduling technology in the MENA region. The project, valued at more than $100 million in revenue, is the largest in Lindsay's history and is part of a broader strategy to support localized food production in the region. Pivot shipments for this project will begin in the fiscal fourth quarter of 2024 and are expected to continue through 2025.

06:52 EDT Avery Dennison appoints Ward Dickson to board of directors - Avery Dennison Corporation announced that its board of directors has appointed Ward Dickson as a director, effective June 1, 2024. Dickson, 61, served as executive vice president and chief financial officer for WestRock Company, a leading sustainable, fiber-based packaging solutions company with $20.3 billion in fiscal 2023 revenues, from July 2015 to November 2021. Dickson served in the same capacity at RockTenn Company, one of WestRock's predecessor companies, from September 2013 to July 2015. He previously served in finance positions of increasing responsibility at Cisco Systems, Inc.

06:51 EDT Spotify raising Spotify Premium prices in the U.S. - Spotify said on its website: "So that we can continue to invest in and innovate on our product features and bring users the best experience, we occasionally update our prices. Over the next month, subscribers in the U.S. will receive an email explaining what this update means for their subscription." Spotify Premium will now cost $11.99 a month, up from the $10.99 increase announced last year. Spotify Duo plans will increase by $2 a month to $16.99 a month, while Family will also increase to $19.99 a month from $16.99 a month. Reference Link

06:49 EDT Takeda presents results from Phase 2b trial of TAK-861 in NT1 - Takeda will present results from its Phase 2b trial of TAK-861 in narcolepsy type 1 as late-breaking data presentations at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society. TAK-861 is an investigational oral orexin receptor 2 agonist and, based on the results, has the potential to provide transformative efficacy in addressing the overall disease burden in people with NT1. The randomized, double-blind, placebo-controlled, multiple dose trial, TAK-861-2001, in 112 patients with NT1 demonstrated statistically significant and clinically meaningful improvements across primary and secondary endpoints, with efficacy sustained over 8 weeks of treatment. NT1 is a chronic, rare neurological central disorder of hypersomnolence caused by a significant loss of orexin neurons, resulting in low levels of orexin neuropeptides in the brain and cerebrospinal fluid. No currently approved treatments target the underlying pathophysiology of NT1. People with NT1 suffer from excessive daytime sleepiness, cataplexy, disrupted nighttime sleep, hypnagogic and hypnopompic hallucinations and sleep paralysis. These debilitating symptoms lead to a markedly reduced quality of life and can severely impact job performance, academic achievement and personal relationships. TAK-861 is designed to address the orexin deficiency in NT1 by selectively stimulating the orexin receptor 2. The presentation highlights results from the Phase 2b trial including: The primary endpoint demonstrated statistically significant and clinically meaningful increased sleep latency on the Maintenance of Wakefulness Test versus placebo across all doses. Improvements were sustained over 8 weeks. Consistent results were achieved in the key secondary endpoints including the Epworth Sleepiness Scale and Weekly Cataplexy Rate, demonstrating significantly improved subjective measures of sleepiness and cataplexy frequency versus placebo that were also sustained over 8 weeks. The majority of NT1 patients in the trial were found to be within normative ranges for MWT and ESS by the end of the 8-week treatment period as a result of these sustained improvements. The majority of the participants who completed the trial enrolled in the long-term extension study with some patients reaching one year of treatment. The trial also included additional exploratory endpoints that showed meaningful improvements in narcolepsy symptoms and functioning according to most participants. These data will also be presented in poster presentations at SLEEP and at future scientific congresses. The dataset showed that TAK-861 was generally safe and well tolerated during the study, with no treatment-related serious treatment-emergent adverse events or discontinuations due to TEAEs. No cases of hepatotoxicity or visual disturbances were reported in the Phase 2b trial or in the ongoing LTE study. The most common TEAEs were insomnia, urinary urgency and frequency, and salivary hypersecretion. Most TEAEs were mild to moderate in severity, and most started within 1-2 days of treatment and were transient. Based on these results, and in consultation with global health authorities, Takeda plans to initiate global Phase 3 trials of TAK-861 in NT1 in the first half of its fiscal year 2024. The Phase 2b data also supported the recent Breakthrough Therapy designation for TAK-861 for the treatment of EDS in NT1 from the U.S. Food and Drug Administration. Breakthrough Therapy designation is a process designed to expedite the development and review of a drug that is intended to treat a serious or life-threatening condition, for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies on at least one clinically significant endpoint.

06:46 EDT Chatham Lodging reports RevPAR up 5% quarter-to-date through May - Chatham Lodging Trust announced RevPAR grew a strong 5 percent quarter-to-date through May, well above its second quarter guidance of 2.5 to 4.0 percent. RevPAR gained 5 percent in both April and May. Key RevPAR growth metrics: April occupancy was up 6 percent to 83 percent with average daily rate down 1 percent to $177; May occupancy was up 4 percent to 82 percent, and ADR also increased 1 percent to $182; RevPAR growth for the Silicon Valley and Bellevue hotels surged 11 percent through May driven by an approximate 6 percent advance in occupancy to 77 percent and a 6 percent rise in ADR to $188; Other strong markets through May were Cherry Creek, Dallas, Greater New York, San Antonio and San Diego. "Driven by the resurgence in business travel around the country, 14 of our 38 comparable hotels generated double digit RevPAR growth through May, leading us to meaningfully outperform the industry and our peers," highlighted Jeffrey H. Fisher, Chatham's chief executive officer and president. "April and May weekday and weekend occupancies were the highest since 2019, and weekday and weekend portfolio ADR exceeded 2019 levels. As occupancies climb, rate growth should accelerate, and this is very encouraging as we enter our busiest time of the year." During the 2024 second quarter, the company: Repaid the Residence Inn Anaheim $29 million maturing mortgage on April 5th; Borrowed an additional $50 million on its term loan on May 3rd; Acquired on May 30th the recently opened, 148-room Home2 Suites by Hilton Phoenix Downtown for $43 million or approximately $293,000 per room; Issued $23 million of CMBS debt secured by the Hyatt Place Pittsburgh North Shore on May 31st; Repaid the Residence Inn Mountain View $35 million maturing mortgage on May 31st; Expects to issue approximately $37 million of CMBS debt during June.

06:41 EDT Agios reports Phase 3 ENERGIZE-T study of mitapivat met primary endpoint - Agios Pharmaceuticals announced that the global Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia achieved its primary endpoint of transfusion reduction response. Statistical significance was also achieved for all key secondary endpoints evaluating additional measures of reduction of transfusion burden compared to placebo. With the positive data generated in the Phase 3 ENERGIZE-T and ENERGIZE studies of mitapivat in patients with alpha- or beta- thalassemia regardless of transfusion needs, the company intends to submit a marketing application for PYRUKYND in the U.S. by the end of 2024 based on all available data from both studies. The company also plans to submit marketing applications in Europe and the Gulf Cooperation Council countries. Topline results for the Phase 3 ENERGIZE-T study were as follows: A total of 258 patients were enrolled in the study, with 171 randomized to mitapivat 100 mg twice-daily and 87 randomized to matched placebo. 155 patients in the mitapivat arm and 83 patients in the placebo arm completed the 48-week double-blind period of the study. The study met its primary endpoint of transfusion reduction response. Treatment with mitapivat demonstrated a statistically significant reduction in transfusion burden compared to placebo, as measured by the TRR endpoint. In the mitapivat arm, 30.4% of patients achieved a transfusion reduction response, compared to 12.6% of patients in the placebo arm. Treatment with mitapivat also demonstrated a statistically significant reduction in additional measures of transfusion reduction response compared to placebo as assessed by the three key secondary endpoints: greater than or equal to50% reduction in transfused RBC units in any consecutive 24-week period through week 48 compared with baseline. greater than or equal to33% reduction in transfused RBC units from week 13 through week 48 compared with baseline. greater than or equal to50% reduction in transfused RBC units from week 13 through week 48 compared with baseline. In addition, a higher proportion of patients in the mitapivat arm compared to the placebo arm achieved the secondary endpoint of transfusion independence. Overall, during the 48-week double-blind period, incidence of adverse events was similar across mitapivat and placebo arms. In the mitapivat arm, 5.8% of the patients experienced an AE leading to discontinuation, compared to 1.2% of patients in the placebo arm. Based on the safety and efficacy data observed in ENERGIZE-T, the company will proceed with the previously stated plans of U.S. regulatory submission by end of this year. Agios plans to present a more detailed analysis of the Phase 3 ENERGIZE-T data at an upcoming medical meeting. Data from the Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent thalassemia will be presented at the European Hematology Association 2024 Hybrid Congress in a plenary session on June 15, 2024, and in a poster session on June 14, 2024.

06:35 EDT Hyatt reports global pipeline of 129,000 rooms - Hyatt Hotels highlighted that its pipeline has grown by nearly 85 percent since 2017, reaching a record 129,000 rooms. This significant growth highlights the strong preference of hotel owners and the strength of the Hyatt brand. Hyatt's commitment to creating the preferred portfolio for high-end guests has resulted in doubling luxury rooms, tripling resort rooms, and quintupling lifestyle rooms since 2017. "Hyatt leading the industry in net rooms growth for seven years is a result of our unique approach to development," said Mark Hoplamazian, president and chief executive officer, Hyatt. "We strategically expand our portfolio of brands, intentionally selecting new and existing markets to enhance our network effect for owners and guests. Our commitment to thoughtful organic growth and strategic acquisitions amplifies our asset-light business model. Our goal is not to be the largest hospitality company, but the company most valued by colleagues, guests, and owners." Additionally, the award-winning World of Hyatt loyalty program has quadrupled its membership since 2017 and is up 22% as of the end of the first quarter of 2024 compared to the same period last year, reaching 46 million members globally. World of Hyatt also has 30 percent more members per hotel than its larger competitors.

06:32 EDT Edwards Lifesciences to sell Critical Care to Becton Dickinson in $4.2B deal - Edwards Lifesciences (EW) has entered into a definitive agreement to sell its Critical Care product group to BD (BDX), in an all-cash transaction valued at $4.2B. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care. Edwards will use the after-tax cash proceeds to fund strategic growth investments. The sale enhances Edwards' balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure. Edwards' goal is to build the most comprehensive structural heart disease portfolio through its pursuit of breakthrough technologies, indication expansions and world-class evidence for its surgical, TAVR and transcatheter mitral and tricuspid innovations, with the focus on helping even more patients around the world. Critical Care will operate in Irvine, CA, and will be led by Katie Szyman, who is currently the corporate vice president of Critical Care for Edwards. The transaction is expected to close by the end of 2024, subject to the satisfaction or waiver of certain closing conditions, including the receipt of required antitrust and foreign investment approvals. If it closes as expected, the impact to adjusted earnings per share in 2024 would be immaterial. Other terms of the agreement were not disclosed.

06:21 EDT Worthington completes acquisition of Hexagon Ragasco - Worthington Enterprises announced the closing of its planned acquisition of Hexagon Ragasco. The business is a global leader in lightweight, customizable LPG composite cylinders used for leisure, household and industrial applications. Andy Rose, president and CEO, Worthington Enterprises, said, "We are excited to welcome the Hexagon Ragasco employees into Worthington Enterprises. We believe Hexagon Ragasco complements our existing cylinder business and accelerates our position in the global propane market. Their composite cylinders are advancing the use of clean fuels as part of the global energy transition especially in developing countries with limited infrastructure."

06:19 EDT AstraZeneca reports Tagrisso plus chemo recommended for approval in EU - AstraZeneca's Tagrisso with the addition of pemetrexed and platinum-based chemotherapy has been recommended for approval in the European Union for first-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, or NSCLC, whose tumours have exon 19 deletions or exon 21 mutations, the company announced.

06:16 EDT Fanhua enters partnership with Baidu AI Cloud to develop 'Du Xiaobao' - FANHUA (FANH) signed a strategic cooperation agreement with Baidu AI Cloud (BIDU) to jointly develop "Du Xiaobao", an AI-Powered insurance sales assistant application equipped with professional service capabilities. This initiative aims to drive the digital and intelligent transformation of the insurance industry, providing insurance agents with a more intelligent and convenient sales experience. Pursuant to the Agreement, the parties will combine their respective resources to jointly develop and operate "Du Xiaobao." Fanhua will provide servers, insurance knowledge data, a product development team, and an expert team, while Baidu will offer large model dialogue, model refining capabilities, and financial model middleware technical support. Baidu will also help upgrade traditional insurance marketing support tools in areas such as language processing, emotional expression, and logical reasoning. This collaboration will enable insurance agents to better respond to market dynamics and customer needs, thereby improving sales efficiency and service quality. The "Du Xiaobao" project is expected to commence beta testing with seed users in June 2024, followed by the official launch of version 1.0 in July 2024. This initial version will utilize intelligent dialogue to provide insurance sales agents with comprehensive support across multiple scenarios, including insurance knowledge Q&A, product consultation, professional development, marketing, and intelligent customer management. The aim is to create a digital personal assistant for every insurance sales agent, leveraging AI technologies such as large models.

06:14 EDT Ideaya Biosciences announces results from darovasertib trial - Ideaya Biosciences announced updated clinical results from the ongoing investigator-sponsored Phase 2 trial of darovasertib, a first-in-class oral, small molecular inhibitor of protein kinase C, or PKC, as neoadjuvant/adjuvant treatment in uveal melanoma, or UM, and clinical update for Phase 2 company-sponsored neoadjuvant UM study. The clinical data from the ongoing investigator-sponsored Phase 2 trial were included in an oral presentation at the American Society of Clinical Oncology, or ASCO, 2024 Annual Meeting. As of the database lock on May 14, 13 patients had completed neoadjuvant treatment, 11 patients received adjuvant darovasertib after primary treatment of their UM, with five patients completing the planned six months of therapy. As of May 14, 2024, 75% had confirmed Eye Saved and approximately 67% observed greater than 30% tumor shrinkage after 6 months. Median tumor shrinkage in 12 enucleation patients was approximately 47% after 6 months. The darovasertib monotherapy neoadjuvant treatment had a manageable adverse event (AE) profile with no drug-related serious adverse events observed. Drug-related AEs were predominantly Grade 1 or Grade 2 and 20% of patients reported at least one drug-related Grade 3 adverse event. The company is targeting a Type C meeting with the FDA to discuss a potential registrational trial for darovasertib in the neoadjuvant UM setting and a clinical efficacy update from its Phase 2 company-sponsored darovasertib neoadjuvant UM trial in H2 2024. As of May 24, 2024 cut-off date, the Phase 2 company-sponsored darovasertib neoadjuvant UM trial has activated over 14 sites globally and enrolled over 40 patients. As of the cut-off date, 8 patients have been on darovasertib treatment for 4-months or more and observed median tumor shrinkage of approximately 40%/25%/72% and the majority of the 6 enucleation patients had reported Eye Saved. In the 8 patients with 4-months or more of darovasertib treatment as of May 24, darovasertib had a manageable AE profile with no drug-related serious adverse events observed, and drug-related AEs were predominantly Grade 1 or Grade 2 and approximately 13% of patients reported at least one drug-related Grade 3 AE. The darovasertib program has ongoing enrollment of a potential registrational Phase 2/3 trial in first-line HLA-A2-negative metastatic UM, and Phase 2 trials in HLA-A2 positive MUM and neoadjuvant and adjuvant UM. Darovasertib received FDA Fast Track designation in MUM and FDA Orphan Drug designation for the treatment of Uveal Melanoma, including MUM. We project the global annual incidence of primary uveal melanoma is approximately 8,000 to 10,000 patients, with the majority of patients in the U.S. and Europe.

06:09 EDT Jack in the Box enters new franchise commitments in Tallahassee, Orlando - Jack in the Box announced significant progress in its Florida expansion plans with new franchise commitments in Tallahassee and Orlando. The details for the franchise expansion plans include future development commitments for five locations in Tallahassee and an additional ten locations in Orlando. Specific locations for each restaurant have not been identified. Florida's dynamic population growth and business-friendly environment were cited as key factors driving the expansion. With over 400 new franchise commitments secured in the last three years, nearly 10% of which are slated for Florida, the company emphasizes its commitment to the Sunshine State.

06:06 EDT AMD announces expanded AMD Instinct GPU roadmap - At Computex 2024, AMD showcased the growing momentum of the AMD Instinct accelerator family during the opening keynote by Chair and CEO Dr. Lisa Su. AMD unveiled a multiyear, expanded AMD Instinct accelerator roadmap which it said will bring an annual cadence of leadership AI performance and memory capabilities at every generation. The updated roadmap starts with the new AMD Instinct MI325X accelerator, which will be available in Q4 2024. Following that, the AMD Instinct MI350 series, powered by the new AMD CDNA 4 architecture, is expected to be available in 2025 bringing up to a 35x increase in AI inference performance compared to AMD Instinct MI300 Series with AMD CDNA 3 architecture. Expected to arrive in 2026, the AMD Instinct MI400 series is based on the AMD CDNA "Next" architecture. "The AMD Instinct MI300X accelerators continue their strong adoption from numerous partners and customers including Microsoft Azure, Meta, Dell Technologies, HPE, Lenovo and others, a direct result of the AMD Instinct MI300X accelerator exceptional performance and value proposition," said Brad McCredie, corporate vice president, Data Center Accelerated Compute, AMD. "With our updated annual cadence of products, we are relentless in our pace of innovation, providing the leadership capabilities and performance the AI industry and our customers expect to drive the next evolution of data center AI training and inference."

06:05 EDT U Power announces follow-on purchase order of battery swapping station - U Power announced a follow-on purchase order from a major taxi operator in Jilin, China. The follow-on order is for the purchase of U Power's advanced dual-mode intelligent battery swapping stations, which feature separate robotic guided vehicles for battery removal and installation. This innovation reduces the battery swapping time from between three to five minutes to two to three minutes. Furthermore, the maintenance cycle of the swapping stations has been optimized, reducing weekly maintenance time by around six hours and enhancing operational efficiency by approximately 15%.

06:04 EDT Walker & Dunlop lists Milhaus Artistry apartment complex - Walker & Dunlop, Inc.'s Midwest Investment Sales team announces its role as the exclusive advisor for Artistry, an iconic mixed use apartment complex in the cornerstone of Indianapolis' urban residential landscape. Comprising 554 units, Artistry presents a prime opportunity to acquire both size and scale in one of the Midwest's most vibrant markets. According to Yardi Matrix, the Indianapolis metro area is the #4 rent growth market in the nation and as RealPage reports, continues to dominate the multifamily leaderboard as one of six US markets forecast to achieve 3%+ 2024 rent growth. The newly acquired Walker & Dunlop Indiana Investment Sales team, led by Steve LaMotte Jr., is a longtime advisor to client, manager and developer, Milhaus. The team is looking to identify a buyer who will acquire the Artistry free and clear or with the option to assume the existing Fannie Mae loan. The buyer will enjoy favorable terms, including a full-term interest-only period at a below- market rate.

06:00 EDT Hipgnosis Songs agrees to increased takeover offer by Blackstone - Blackstone (BX) has announced plans to sweeten its offer for Hipgnosis (HPGSF) as part of a restructured bid for the music rights owner designed to make completing the deal easier, and is increasing its offer to $1.31 per share from $1.30. The Revised Offer values Hipgnosis' entire issued, and to be issued, ordinary share capital at approximately $1.584B. Blackstone said the increase in price "has come about as a result of discussions between and in part reflects Hipgnosis incurring lower adviser fees in respect of the transaction than previously expected." Reference Link

05:44 EDT Summit Therapeutics receives $200M investment from institutional investor - Summit Therapeutics announced that the company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the company's common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, for aggregate gross proceeds to the company of approximately $200M. Summit intends to use the net proceeds to advance the clinical development of ivonescimab, and for working capital and general corporate purposes. The securities described above have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. Summit has agreed to file a registration statement with the SEC registering the resale of the shares of common stock and shares of common stock issuable within 60 days of the closing of the securities purchase agreement. In addition, Summit announced an expansion of its license territories for ivonescimab via an amendment of the collaboration and in-license agreement with Akeso. Under the terms of the expanded agreement, Summit's license territories for ivonescimab will include Latin America, including Mexico and all countries in Central America and South America, in addition to the Middle East and Africa. This expansion adds to the territory licensed by Summit, which previously included the United States, Canada, Japan, and Europe. In exchange for these rights, the total deal value is worth up to $70M. Consistent with the original governing collaboration agreement are the remaining provisions, including royalty payments, manufacturing provisions, and other business terms. The amendment also strengthens the partnership for both parties by increasing the mutual data sharing benefits for all trials involving ivonescimab worldwide, which may help facilitate clinical development and regulatory approval processes in various regions.

05:27 EDT Immutep enters clinical collaboration with Merck - Immutep (IMMP) announced that it has entered into a clinical trial collaboration and supply agreement with Merck (MRK), through a subsidiary, to evaluate eftilagimod alfa in combination with MSD's anti-PD-1 therapy, Keytruda and chemotherapy for the first-line treatment of metastatic non-small cell lung cancer, or NSCLC, in a pivotal Phase III trial. The potential for efti in combination with Keytruda and chemotherapy is to set a new standard of care, by strengthening clinical outcomes for responders and broadening the number of patients who respond across the entire NSCLC patient population regardless of PD-L1 expression. This collaboration follows two previous collaborations for the TACTI-002 Phase II and TACTI-003 Phase IIb trials, which collectively treated over 350 patients. Under the terms of the agreement, Immutep will conduct the registrational TACTI-004 study and MSD will supply Keytruda. The agreement enables Immutep and MSD to seek marketing authorization of the combination and to market their respective compounds with a relevant label indication. The parties retain the commercial rights to their respective compounds and are free to conduct other clinical studies, either individually or in combination, in any therapeutic area. The clinical data generated by the innovative immuno-oncology combination of Immutep's MHC Class II agonist and MSD's anti-PD-1 therapy in the TACTI-002 Phase II trial in first-line NSCLC regardless of PD-L1 expression has led to oral presentations at the ASCO, SITC, and ESMO conferences. Efti's unique activation of dendritic cells engages the adaptive and innate immune system to drive a broad anti-cancer immune response, including proliferation of cytotoxic T cells that complements anti-PD-1 therapy in first-line NSCLC across all levels of PD-L1 expression. Notably, over 75% of the patients in both the TACTI-002 and INSIGHT-003 clinical trials had a PD-L1 Tumor Proportion Score of less than50%, and both studies have shown strong efficacy in these patients with low and negative PD-L1 expression who are typically less responsive to anti-PD-1 therapy. Furthermore, the triple combination of efti, Keytruda and carboplatin/pemetrexed in INSIGHT-003 has been well tolerated.

05:17 EDT Qiagen expands QIAstat-Dx testing menu in the U.S. - Qiagen announced the launch of the QIAstat-Dx Gastrointestinal Panel 2 in the United States. The launch comes after the recent clearance of the syndromic test for clinical use by the FDA and marks a significant step forward in improving the accuracy and efficiency of gastrointestinal infection diagnosis.

05:12 EDT Ericsson announces conclusion of monitorship by DOJ - Ericsson announced the conclusion of the work and term of the independent compliance monitor appointed by the U.S Department of Justice, or DOJ, in June of 2020 in connection with Ericsson's 2019 Deferred Prosecution Agreement, or DPA, to resolve historical violations of the Foreign Corrupt Practices Act, or FCPA. The March 2023 plea agreement with the DOJ that followed non-criminal breaches of the DPA has also expired as of June 2. The role of the independent compliance monitor over the past four years has been to comprehensively review, assess, evaluate and test all aspects of the company's global anti-corruption compliance program and internal controls. On March 28, the monitor certified to DOJ that Ericsson's anti-corruption compliance program has satisfied requirements and is functioning effectively.

05:05 EDT Nokia, Gati Shakti Vishwavidyalaya sign MoU for research collaboration - Nokia signed a memorandum of understanding, or MoU, with Gati Shakti Vishwavidyalaya, or GSV, to pursue research and development opportunities in the areas of transportation and logistics in India. The research collaboration agreement will bring together Nokia's telecommunication and research expertise with GSV's expertise in transportation and logistics. The MoU was signed at Rail Bhawan, New Delhi, in the presence of Sh. Ashwini Vaishnaw and senior officials. Nokia and Gati Shakti Vishwavidyalaya will collaborate on research opportunities in 5G/6G communications targeting air, land and sea transportation use cases, as well as standards development, smart factory/automation, and AI/GenAI labs. The collaboration has a research focus specifically on leveraging Nokia's Network as Code platform with developer portal and digital twins for transportation and logistics sectors, fiber sensing and AI, and optical network planning. The Network as Code platform with developer portal reflects Nokia's strategic focus to drive new business models and unlock the potential that networks can deliver in terms of innovation, sustainability, and productivity. It enables developers and operators to accelerate the work of producing software applications for enterprises, industrial entities, and consumers, and monetizing 5G and 4G network assets beyond basic connectivity. GSV, a Central University created by the Act of Parliament, operates under the Ministry of Railways with a mandate to cover the entire transportation and logistics sectors in India for multidisciplinary education, research, skilling and executive education.